Global Clinical Development -General Medicine 
Secukinumab (AIN457)
Clinical Trial Protocol CAIN457A2324  / [STUDY_ID_REMOVED] 
A randomized, double -
blind, multic enter study assessing short 
(16 weeks) and long -term efficacy (up to 1 y ear), safet y, and 
tolerability of sub-cutaneous secukinumab in subjects of body 
weight 90 kg or higher w ith moderate to severe chronic plaque-ty pe 
psoriasis 
Document type: Clinical Trial Protocol
EUDRACT number: 2015 -0046 20-60
Version number: 00 (Original Protocol)
Clinical trial phase: IIIB
Release date: 18-Dec- 2017
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Template Version 3.2 (July 2016)

[COMPANY_001] Confidential Page 2
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Table of contents
Table of contents ................................................................................................................. [ADDRESS_148457] of abbreviations ............................................................................................................ 6
Glossary  of terms ................................................................................................................. 8
Protocol summary .............................................................................................................. 10
1Introduction ....................................................................................................................... 13
1.1 Background ............................................................................................................ 13
1.2 Purpose .................................................................................................................. 14
2Study  objectives and endpoints ......................................................................................... 14
2.1 Objectives and related endpoints ........................................................................... 14
3Investigational plan ........................................................................................................... 17
3.1 Study  design ........................................................................................................... 17
3.2 Rationale for stud y design ..................................................................................... 19
3.3
Rationale for dose/regimen, route of administration and duration of treatment ....20
3.4 Rationale for choice of comparator ....................................................................... 21
3.5 Purpose and timing of primary  endpoint anal ysis/design adaptations
................... 21
3.6 Risks and benefits .................................................................................................. 21
4Population .......................................................................................................................... 23
4.1 Inclusion criteria .................................................................................................... 23
4.2 Exclusion criteria ................................................................................................... 24
5Treatment ........................................................................................................................... 26
5.1 Study  treatment ...................................................................................................... 26
5.1.1 Investigational and control drugs .......................................................... 26
5.1.2 Additional treatment .............................................................................. 26
5.2 Treatment arms ...................................................................................................... 26
5.3
Treatment assignment and randomization............................................................. 27
5.4 Treatment blinding ................................................................................................. 27
5.4.1 Unblinding for primary  endpoint analy sis............................................ 28
5.5 Treating the patient ................................................................................................ 28
5.5.1
Patient numbering ................................................................................. 28
5.5.2 Dispensing the stud y drug ..................................................................... 28
5.5.3 Handling of study  and additional treatment .......................................... 29
5.5.4 Instruc tions for prescribing and taking study  treatment ........................ 30
5.5.5 Permitted dose adjustments and interruptions of study  treatment ........ 31

[COMPANY_001] Confidential Page 3
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
5.5.[ADDRESS_148458] -study treatment .......................................... 34
5.6.2 Discontinuation of study  treatment ....................................................... 34
5.6.3 Withdrawal of informed consent ........................................................... 35
5.6.4 Loss to follow -
up .................................................................................. 36
5.6.5 Early study  termination by  [CONTACT_456] ................................................. 36
6
Visit schedule and assessments ......................................................................................... 36
6.1 Information to be collected on screening failures .................................................. 41
6.2 Patient demographics/other baseline characteristics ............................................. 41
6.2.1 Demographics ....................................................................................... 41
6.2.2
Psoriasis medical history / previous psoriasis therapi[INVESTIGATOR_014] ....................... 41
6.2.3 Smoking history .................................................................................... 41
6.2.4 Co-morbidities –cardiovascular medical history ................................. 41
6.2.5 Relevant medi cal history/current medical conditions ........................... 41
6.2.6
Determination of the tuberculosis status............................................... 42
6.2.7 Other b aselin e char acteristics................................ ................................ 44
6.3 Treatment exposure and compliance ..................................................................... 45
6.4 Efficacy .................................................................................................................. 45
6.4.1 Investigator Global Assessment (IGA mod 2011) ................................ 45
6.4.2 Assessment of total Body surface Area and Psoriasis Area Severit y 
Index ...................................................................................................... 46
48
6.4.4 Appropriateness of efficacy  assessments .............................................. 48
6.5 Safety ..................................................................................................................... 48
6.5.1 Physical examination ............................................................................ 49
6.5.2 Vital signs .............................................................................................. 49
6.5.3 Height and weight ................................................................................. 49
6.5.4 Laboratory  evaluations .......................................................................... 50
6.5.5 Electrocardiogram (ECG) ..................................................................... 51
6.5.6 Pregnancy  and assessments of fertility ................................................. 51
52
52

[COMPANY_001] Confidential Page 4
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
52
53
53
54
7Safety  monitoring .............................................................................................................. 54
7.1 Adverse events ....................................................................................................... 54
7.2 Serious adverse events ........................................................................................... 56
7.2.1 Definition of SAE ................................................................................. 56
7.2.2 SAE reporting
........................................................................................ 57
7.3 Liver safety  monitoring ......................................................................................... 58
7.4 Reporting of stud y treatment errors including misuse/abuse ................................ 59
7.5 Pregnancy  reporting ............................................................................................... 59
8Data review and database management ............................................................................. 60
8.1 Site monitoring ...................................................................................................... 60
8.2
Data collection....................................................................................................... 60
8.3 Database management and quality  control ................................ ............................ 61
8.4 Data Monitoring Committee .................................................................................. 61
8.5 Adjudication Committee ........................................................................................ 62
9Data analy sis...................................................................................................................... 62
9.1 Analy sis sets .......................................................................................................... 62
9.2
Patient demographics and other baseline characteristics....................................... 62
9.3 Treatments ............................................................................................................. 62
9.4 Analy sis of the primary  variable(s) ....................................................................... 63
9.4.1 Primary  Variable(s) ............................................................................... 63
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 63
9.4.3 Handling of missing values/censoring/discontinuations ....................... 64
9.4.4 Sensitivity  analy ses............................................................................... 64
9.5 Analy sis of secondary  variables
............................................................................ 64
9.5.1 Efficacy  variables.................................................................................. 64
9.5.2 Safety
 variables ..................................................................................... 65
66
66
67
67
67
67

[COMPANY_001] Confidential Page 5
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
9.7 Interim Anal yses................................ ................................ ................................ ....68
9.8 Sample size calculation.......................................................................................... 69
10Ethical considerations ........................................................................................................ 69
10.1 Regulatory
 and ethical compliance ........................................................................ 69
10.2 Informed consent procedures
................................................................................. 69
10.3 Responsibilities of the investigator and IRB/ IEC.................................................. 70
10.4 Publication of study  protocol and results ............................................................... 70
10.5 Quality  Control and Quality  Assurance ................................................................. 70
11Protocol adherence ............................................................................................................ 71
11.1 Protocol amendments ............................................................................................. 71
12References ......................................................................................................................... 71
13Appendices ........................................................................................................................ 73
13.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 73
13.2 Appendix 2: L iver ev ent and Laboratory  trigger Definitions and Follow
-up 
Requirements ......................................................................................................... [ADDRESS_148459] of tables
Table 2
-1 Objectives and related endpoints ................................ .......................... 15
Table 3-1 Exposure to 300 mg s.c. every  2 weeks in completed trials ................. 22
Table 5-1 Prohibited medica tion........................................................................... 32
Table 6
-1 Assessment schedule ............................................................................. 38
Table 6
-2 The IGA mod 2011 ra ting scale ............................................................ 45
Table 6
-3 The PASI  scoring s ystem...................................................................... 46
Table 7
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... [ADDRESS_148460] of figures
Figure 3-1 Study  design .......................................................................................... 17
Figure 3 -
2 Predicted s ystemic exposure with secukinumab 300 mg given 
every  2 weeks or every  4weeks during maintenance .......................... 20
Figure 6 -1 Tuberculosis screening flowchart ......................................................... 44

[COMPANY_001] Confidential Page 6
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
List of abbreviations
AE Adverse Event
Alb Albumin
ALT Alanine Aminotransferase
ALP Alkaline Phosphatase
AST Aspartate Aminotransferase
ATC Anatomical Therapeutic Chemical (ATC)
BDR Bioanalytical Data Report
β-hCG β-subunit of hCG gonadotropin
BSA Body Surface Area
CD Cluster of differentiation
CFR US Code of Federal Regulations 
CHMP Committee for medicinal products for human use
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CS Corticosteroid
CT Computerized tomography
ECG Electrocardiogram
eCRF Electronic Case Report Forms
EDC Electronic Data Capture
e.g. Exemplī grātiā (for example)
EOT End of treatment
EU European Union
FAS Full analy sis set
FDA Food and Drug Administration
GCP Good Clinical Practice
GGT Gamma -Glutamyl Transferase
hCG Human chorionic gonadotropin
IB Investigator’s Brochure
ICF Informed consent form
ICH International Council for Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use
i.e. of id est (in other words)
IEC Independent Ethics Committee
IGA Investigator’s Global Assessment
IGA mod Investigator’s Global Assessment modified
IL Interleukin

[COMPANY_001] Confidential Page 7
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
i.v. Intravenous
IRB Institutional Review Board
IRT Interactive Response Technology
LFT Liver function test 
LLN Lower Limit of Normal
MedDRA Medical dictionary for regulatory activities 
MI multiple im putation
MRI Magnetic resonance imaging
PASI Psoriasis Area and Severity Index
PEA Primary endpoint analysis (PEA)
PFS pre-filled syringes
Q2 / Q2 W Every 2 weeks
Q4 / Q4 W Every 4weeks
QFT QuantiFERON TB -Gold test
SAE Serious Adverse Event
s.c. subcutaneously
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutam ic-pyruvic transaminase
TB Tuberculosis
TBL Total bilirubin
TNFα Tumor necrosis factor alpha
[LOCATION_003] [LOCATION_002] of America
[LOCATION_006] [LOCATION_008]
ULN Upper Limit of Normal
UV Ultraviolet
WBC White blood cells
WoCBP Women of child bearing potential

[COMPANY_001] Confidential Page 8
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Glossary  of terms
Cohort A specific group of patients/subjects fulfilling certain criteria
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve blinding 
of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigational drug
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 10 0mg
once a day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web-based applications, 
interactive voice response sy stems and clinical laboratory interfaces.
EDC includes the use of Electronic Case Report Forms (eCRFs) which are 
used to capture data transcr ibed from paper source forms used at the point of 
care.
Enrollment Point/time of subject entry into the study at which informe d consent must be 
obtained (e.g. prior to starting any of the procedures described in the 
protocol)
Investigational drug The drug whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synony mous with 
“investigational new drug” or “investigational medicinal product.”
Medication pack 
numberA unique identifier on the lab el of each investigational drug package
Part A single component of a study which contains different objectives or 
populations within that single study. Common parts within a study are: a 
single dose part and a multiple dose part, or a part in subjects with 
established disease and in those with newly -diagnosed disease.
PASI 90 response Subjects achieving ≥ 90% improvement (reduction) in PASI score compared 
to baseline
Patient/subject ID A unique number assigned to each subject upon signing the informed 
consent 
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) 
which are described in the Protocol. Periods define the study phases and wil l 
be used in clinical trial database setup and eventually in analy sis
Randomization 
numberA unique identifier assigned to each randomized subject , corresponding to a 
specific treatment arm assignment
Source 
Data/DocumentSource data refers to the initial record, document, or primary  location from 
where data comes. The data source can be a database, a dataset, a 

[COMPANY_001] Confidential Page 9
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
spreadsheet or even hard -coded data.
Study drug/ treatment Any single drug or combination of drugs administered to the subject as part of 
the required study procedures; includes investigational drug (s), 
placebo/comparator active drug run -ins or background therapy
Study Treatment 
DiscontinuationWhen the subject permanently stops taking study treatment prior to the 
defined study treatment completion date 
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested in 
the st udy
Withdrawal of study 
consentWithdrawal of consent from the study is defined as when a subject does not 
want to participate in the study any longer, and does not want any further 
visits or assessments, and does not want any further study related contac t, 
and does not allow analysis of already obtained biologic material

[COMPANY_001] Confidential Page 10
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Protocol summary
Protocol numberCAIN457A2324
Full Title A randomized, double -blind, multicenter study  assessing short (16week s) 
and long-term efficacy (up to 1 year), safety, and tolerability of 
sub-cutaneous secukinumab in subjects of body weight [ADDRESS_148461] -marketing commitment to the FDA ([LOCATION_003]).
Primary Objective(s) To demonstrate the efficacy  of secukinumab 300mgevery [ADDRESS_148462] to
Investigator’s Global Assessment (IGA) mod 2011 0 or 1 response at 
Week16.
To investigate the clinical safety  and tolerability of secukinumab 300mg
every 2 weeks in comparison to secukinumab 30 0mgevery 4 weeks
Study design This is a 52 -week multicenter, randomized, double -blind, parallel -group trial 
in approximately 330subjects with moderate to severe chronic plaque -type 
psoriasis of body weight 90 kg or higher at time of randomization.
The study consists of 4 period s: screening (up to 4weeks ), treatment 
Period 1 (16week s), treatment Period 2 (36 weeks), and post-treatment 
follow -up(8 weeks) . 
Subje cts will be randomized using a 1:1 ratio to the following groups: 
Secukinumab 300mg every  2 weeks ; Secukinumab 300mg every 
4weeks . 
 
 
 
 
Population The study population will consist of approximately 330 adult male and 
female subjects (≥ 18 years old) with moderate to severe chronic plaque -

[COMPANY_001] Confidential Page 11
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
type psoriasis of body weight of ≥ [ADDRESS_148463] 18 years of age at time of screening.
4.Body weight o f ≥[ADDRESS_148464] 6months and 
diagnosed before randomization.
6.Moderate to severe psoriasis as defined at randomization by:
Psoriasis Area and Severity Index (PASI )score of 12 or greater, 
and
IGA mod 2011 score of 3 or greater (based on a static scale of 0 –
4), and
Body Surface Area (BSA) affected by [CONTACT_109010] -type psoriasis of 10% 
or greater.
7.Candidate for systemic therapy. This is defined as a subject having 
moderate to severe chronic plaque -type psoriasis that is inadequately 
controlled by :
topi[INVESTIGATOR_131525]/or,
phototherapy and/or,
previous s ystemic therapy .
Key Exclusion criteria 1.Form s of psoriasis other than chronic plaque -type (e.g., pustular, 
erythrodermic and guttate psoriasis) at screening or Randomization.
2.Ongoing use of prohibited treatments. Washout period s detailed in the 
protocol have to be adhered to (Table 5-1). Subjects not willing to limit 
UV light exposur e (e.g., sunbathing and / or the use of tanning devices) 
during the course of the study  will be considered not eligible for this 
study since UV light exposure is prohibited . Note: administration of live 
vaccines 6 weeks prior to Randomization or during thestudy  period is 
also prohibited. 
3.Previous exposure to secukinumab (AIN457) or any other biologic drug 
directly targeting Interleukin -17 (IL-17) or the IL -[ADDRESS_148465] has returned to baseline, whichever is longer; 
or longer if required by [CONTACT_427].
5.Pregn ant or nursing (lactating) women
6.History of lymphoproliferative disease or any known malignanc y or 
history of malignancy of any organ system treated or untreated within 
the past 5 years, regardless of whether there is evidence of local 
recurrence or metastases (except for skin Bowen’s disease, or basal 
cell carcinoma or actinic keratoses that have been treated with no 

[COMPANY_001] Confidential Page 12
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
evidence of recurrence in the past 12 weeks; carcinoma in situ of the 
cervix or non-invasive malignant colon polyps that have been 
removed).
7.History of hypersensitivity to any of the study drug constituents.
Study treatment Secukinumab 150mgsolution for sub-cutaneous injection in a 1 ml 
pre-filled syringe
Placebo solution for sub-cutaneous injection in a 1 ml pre -filled syringe
Efficacy assessments Investigator’s Global Assessment for general psoriasis (IGA mod 2011; 
scale from 0 –4)
Psoriasis Area and Severity Index (PASI; score from 0 –72)
 
Key safety 
assessmentsEvaluation of all AEs and SAEs
Physical examination
Vital signs
Height and weight
ECG
Laboratory evaluations (e.g. hematolog y, clinical chemistry , urinalysis )
Pregnancy
 
Data analysis The hypotheses will be tested sequentially and are included in a 
hierarchical testing strategy. Type-I-errors are set to keep a family -wise 
type-I-error of 2.5% (one -sided):
H1: secukinumab 300mg every [ADDRESS_148466] toPASI 90response at 
Week16.
H2: secukinumab 300mg every [ADDRESS_148467] toIGA mod 2011 0 or 1
response at Week16.
The testing sequence will continue to H2at α(one-sided) only if H1has 
been rejected.
The primary analy sis method will be the logistic regression with treatment 
group, and baseline weight, baseline PASI score as explanator y variable s. 
Odds ratios will be computed for comparisons between treatment arms
utilizin g the logistic regression model fitted. In case of response rates of 0% 
or of 100% in one of the treatment groups, Fisher’s exact test will be 
applied . Confidence intervals for risk difference will be provided. Multiple 
imputation method will be used for handling missing data.
Key words psoriasis, PASI, IGA mod 2011, secukinumab, pre -filled syringes

[COMPANY_001] Confidential Page 13
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
1 Introduction
1.1 Background 
Psoriasis is a chronic relapsing disease of the skin characterized by [CONTACT_109011]. 
The lesions are classified as erythrosquamous, which indicates that both the vasculature 
(erythema) and the epi[INVESTIGATOR_49196] (increased scale formation) are involved . 
Plaque -type psoriasis (also called plaque or chronic plaque psoriasis) is the most frequent 
clinical presentation and therefore, also called psoriasis vulgaris. The erythematous plaques 
are well defined with sharp borders. The silvery grey scale on the surface of the lesions is 
easily  removed. Sharply  demarcated lesions can present on the extensor surfaces of the knees 
and elbows and on the trunk. Lesions are often symmetrically  distributed. The size of the 
lesions is highly  variable. Psoriasis may also occur on the scalp, palms and/or soles 
(palmoplantar psoriasis), nails and in skin folds (intertrigo psoriasis). The amount of psoriasis 
covering the body  can be measured roughly  as a percentage of body  surface area, using the 
handprint to represent 1% of the body  surface. In approx imately  one-third of patients, more 
than 10% of the body  is covered, and this is termed moderate to severe psoriasis. Clinical 
disease can also be assessed by  a trained health -care practitioner, using the Psoriasis Area and 
Severity  Index (PASI ) score. This tool ranks severit y of erythema (redness), induration 
(thickness), and desquamation (scale) and area affected by [CONTACT_131544], with [ADDRESS_148468] 12 is usually  required to classify 
for moderate to severe psoriasis.
Treatment of moderate to severe psoriasis wasbased on phototherapy , conventional systemic 
treatment (e.g. methotrexate, cyclosporine, acitretin) and biologics (tumor necrosis factor 
alpha (TNFα) -inhibitors etanercept, infliximab and adalimumab).The primary  indication for 
these biological products is the treatment of moderate to severe psoriasis not responding 
satisfactoril y to phototherap y and conventional systemic treatment such as methotrexate or 
acitretin.
Extensive clinical experie nce with TNFα -inhibitors has been collected over the past 10 years 
and these agents are generall y considered to be effective and relativel y safe ( Papp et al 2006). 
However, a substantial percentage of patients do not respond well to treatment with TNFα -
inhibitors. 
This inadequate response may imply either a primary  failure (e.g. not achieving a 
decrease in Psoriasis Area and Severity  Index (PASI ) score of at least 50% after adequate 
duration of treatment) , secondary  failure (an initially  adequate response that is lost over time) 
or intolerance for the TNFα -inhibitor. The percentage of patients with an inadequate response 
to TNFα -inhibitors can be as high a s 40 to 60% ( van Lümig et al 2010 ).
The arrival of a new class of sy stemic, biological drugs such as ustekinumab (interleukin (IL)-
12/23 inhibitor) has provided clinicians with more treatment options. Ustekinumab has shown 
good clinical efficacy  in a number of well-designed Phase 3 studies (Papp et al 2008). PASI 
response rates were better than those of etanercept and comparable to PASI response rates of 
infliximab and efficacy  was generall y maintained up to 3 years after initiation of treatment 
(Kimball et 
al 2012). Additionally , a number of IL-17A and IL-17RA inhibitors are 
investigated for the treatment of a range of immune mediated inflammatory dis eases. 

[COMPANY_001] Confidential Page 14
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Secukinumab (AIN457) is a recombinant high-affinity  fully human monoclonal anti-human 
IL-17A antibody  of the immunoglobulin (Ig) G1/κ- class. Secukinumab binds to human 
IL-17A and neutralizes the bioactivity  of this cytokine. IL-17A is the central cytokine of a 
newly  defined subset of inflammatory  T cells, the Th17 cells which, in several animal models, 
are pi[INVESTIGATOR_108988]. IL-17A is mainly  produced 
by [CONTACT_121913]4+ and CD8+ T lymphocy tes and is being recognized as one of the 
principal pro-inflammatory  cytokines in immune mediated inflammatory  diseases. Its 
neutralization is expected to treat the underl ying pathoph ysiology  of immune mediated 
disease, and as a consequence provide relief of psoriatic symptoms. Secukinumab has been 
shown to be superior to etanercept (Langley  et al 2014) and superior to ustekinumab 
(Thaci et
al2015) in clearing skin ofsubjects with moderate to severe psoriasis with 
comparable safet y profile.
Secukinumab (Cosent yx®) was approved in 2014 in Japan, in 2015 in the US (FDA 2014) , in 
the European Union
(EU), in Switzerland and in other countries for the treatment of moderate 
to severe plaque psoriasis in adults, with a recommended dose of 300mgby [CONTACT_131545] 0, 
1, 2 and 3, followed by [CONTACT_131546] 4. Secukinumab is available as a powder for solution for injection, and as a 
solution of 150mgin 1 mL for injection in pre-filled syringe or pre-filled pen. Currently  two 
injections are required for the administration of the recommended dose.
As of 25 Jun 2017, over 11,000 subjects (healthy  subjects and patients) have received 
secukinumab in [COMPANY_001] sponsored clinical studies at doses ranging from 0.1mg/kg to 
30mg/kg intravenously  (i.v.), and from 25mg to 300mgsubcutaneously  (s.c.), given as 
single or multiple doses. Full safet y results including all reported AEs are currentl y available 
for completed studies across different indications. In general, these results show comparable 
numbers of adverse events (AEs) in subjects treated with secukinumab comp ared to placebo 
without indication of any specific organ toxicity . The Investigator’s Brochure (IB) provides a 
more detailed review of the pre -clinical and clinical information on secukinumab.
1.[ADDRESS_148469]-marketing commitment to the FDA ([LOCATION_003]). Refer to Section 3.2
for detail on commitment. 
2 Study  objectives and endpoints
2.1 Objectives and related endpoints
The objectives and related endpoints presented in Table 2-1will be evaluated in subjects with 
body  weight of 90kg or higher at randomization and with moderate to severe chronic plaque -
type psoriasis.

[COMPANY_001] Confidential Page 15
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary Objective(s) Endpoint(s) for primary objective(s) 
To demonstrate the efficacy  of secukinumab 
300mgevery  [ADDRESS_148470] to PASI 90 response at Week 16Endpoint: PASI  90response 
Description: P ercentage of subject s who 
achieve ≥ 90% reduction in PASI  score 
compared to baseline 
Time frame: 16 weeks
Secondary Objective(s) Endpoint(s) for secondary objective(s)
To demonstrate the efficacy  of secukinumab 
300mgevery  [ADDRESS_148471] to Investigator’s Global Assessment 
(IGA) mod 2011 0 or 1 response at 
Week 16.Endpoint: I GA mod 2011 0 or 1 response 
Description: P
ercentage of subject s who 
achieve IGA mod [ADDRESS_148472] 2 points onthe IGA scale 
compared to baseline.
Time frame: 16 weeks
To investigate the clinical safet y and 
tolerability  of secukinumab 300 mgevery  2 
weeks in comparison to secukinumab 
300mgevery  4 weeksEndpoint: Clinical safety and tolerability .
Measure: vital signs, clinical laboratory  
variables, ECGs, Adverse Events monitoring
Time frame: up to 52 weeks

[COMPANY_001] Confidential Page 16
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324

[COMPANY_001] Confidential Page 17
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
3 Investigational plan
3.1 Stud y design
This is a 52-week multicenter, randomized, double -blind, parallel -group trial in approximately  
330subjects with moderate to severe chronic plaque -type psoriasis of body  weight 90kgor 
higher at time of randomization.
The study  consists of 4 period s: screening (up to 4weeks ), treatment Period 1 (16 weeks), 
treatment Period 2 (36 weeks), and follow -up(8 weeks). 
Safety , efficacy ,  o
f 
secukinumab will be performed. 
An outline of the study  design is presented in Figure 3-1and a detailed visit and assessment 
schedule in Table 6 -1.
Figure 3-1 Study  design 
EOT1/2: End of treatment 1/2      Q2W ks
/Q4Wks:Every 2/4weeks
Screening Period (Screening to Randomization)
The screening period of at least [ADDRESS_148473]’s 
eligibility  and to taper subjects off prohibited medications . 

[COMPANY_001] Confidential Page 18
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Treatment Period 1 (Randomization to Week 16pre-dose)
The Treatment Period 1 is the period from randomization (baseline) through Week 16prior to 
dosing . At the start of treatment Period 1, eligible subjects will be randomized via Interactive 
Response Technology  (IRT) using a 1:1 ratio to one of the following treatment groups:
Secukinumab 300 mgevery  2 weeks 
Secukinumab 300 mgevery  4 weeks
Refer to 
Section 5.2 for details on treatment arms. 
All subjects will receive 2 injections of secukinumab 150mgonce weekly  for four weeks (at 
Randomization, weeks 1, 
2 and 3).Thereafter the frequency  of secukinumab/placebo 
injections will be as per the treatment groups assigned at baseline. To maintain the treatment 
blind, subject sassigned to receive secukinumab 300mgevery  4 weeks will also receive two 
placebo injections (2 x secukinumab placebo 150 mgs.c.) every  4weeks starting at Week 6
(seeFigure 3 -1).
Subjects who complet e treatment Period 1 will enter treatment Period 2. For all subjects who 
discontinue study  t reatment prematurely  f or any reason before the 
EndofTreatment Period 1/Week 16visit (EOT 1) , an EOT [ADDRESS_148474] dose of study  drug and then subjects should enter the 
treatment free follow -upperiod. 
Treatment Period 2 (Week 16post -dose to Week 52)
Treatment Period [ADDRESS_148475] dose will be administered at Week 48. 
Subjects from the 30 0mgevery  2 weeks group will remain on secukinumab 30
0mgevery  
2 weeks until the end of treatment
Subjects from the 30 0mgevery  4 weeks group: 
 
 
 
This allocation will be based on a pre-assignment done at the randomization/ba seline 
visit.
The planned end of treatment period 2 visit (EOT 2 )will be performed at Week 52. 
For all subjects who discontinue study  treatment prematurel y for any reason before the end of 
treatment period 2/Week 52 
(EOT2 ), an EOT2 visit should be performed approximately  
4weeks after their last dose of study  drug and then subjects should enter the post treatment 
follow -upperiod.

[COMPANY_001] Confidential Page 19
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Post treatment f ollow -up period
All subjects should enter the post treatment follow -upperiod, which includes the F4 and F8 
follow -up visits. No study  treatment (secukinumab) is administered during this period. 
Follow -upvisit F4 is approximately  4 weeks after the EOT 1/EOT [ADDRESS_148476] study  treatment administra tion. Follow -upvisit F8 is approximately 8 weeks after the 
EOT 1/EOT [ADDRESS_148477] approval commitment to the [LOCATION_002] Food and 
Drug Administration 
(FDA). The FDA requested a clinical trial to :
evaluate the treatment effect and safet y profile of a higher exposure of secukinumab in 
psoriasis subjects with higher bod y weight and 
 
The request was based on the FDA’s exposure -respon se analysis which suggest edthat IGA 
0/1 response rate in subjects with body  weight ≥ 90 kg administered 300mgmay be further 
increased if exposures are increased  
The randomized, double -blind, parallel -group design of this study  is aligned with previous 
studies performed in the indication of plaque psoriasis and registration secukinumab studies.
The blinding will be maintained throughout the study  to ensure reliable efficacy  and 
safet y 
measures of the 300mgevery  2  weeks regimen and its comparison to the 300mgevery 
4weeks regimen .
The primary  endpoint  is PASI  90 assessed at Week 16. PASI  90 
was chosen as the primary  efficacy  variable to represent the therapeutic goal recognized by 
[CONTACT_131547] y of Dermatology  and European Medicines Agency  as “measure of 
optimal response” or “treatment success”. By [CONTACT_10585] 16subject s woul d have the greatest 
chance of reaching maximum efficacy  with secukinumab therapy , as established in the 
registration Phase 3 studies (PASI 90 response was around 70%).  
 
 
 
 
The study ’s design
,with a total treatment duration of 52 weeks, will allow assessment of long 
term efficacy  and safety  of the two dose regim ens and is aligned with previous studies 
performed in the indication of plaque psoriasis and registration secukinumab studies.

[COMPANY_001] Confidential Page 20
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
Secukinumab 300mgs.c.with an initial weekl y induction schedule up to 4weeks followed 
by a s.c administration of every  four weeks up to Week 48 is based on the secukinumab Phase
3 registration program.
A higher monthly  dose regimen than the one approved for the psoriasis indication has been 
included in the study  as requested by [CONTACT_8415]. This higher monthly  dose regimen is being 
assessed to see if improvement in response is achievable in subjects with body  weight ≥90 kg, 
while maintaining a favorable safet y profile.
Systemic expos urevarie swith body weight in an allometric relationship. For clearance
, the 
allometric exponent wasestimated to be close to 1; in other words, a doubling of bod y weight 
could lead to a nearl y 2-fold increase in clearance and therefore reduced serum expo sure 
(Bruin et 
al 2017 ).Therefore, evaluation of a dosing regimen with higher exposure than 
resulting from the marketed regimen is appropriate in this heavier subject population.
Based on a large database of Phase II and Phase III double -blind randomized 
placebo
-controlled studies including 1,405 subjects treated with secukinumab , a clear 
dose/exposure response relationship was established. Serum secukinumab concentration was 
by [CONTACT_131548] . 
As shown in Figure 3-2, which presents predicted secukinumab concentration based on 
population pharmacokinetics models in psoriasis , shows that increasing the dose regimen 
from 300mgevery  4 weeks to 300mgevery  2  weeks after the induction period would result 
in a sustained higher secukinumab serum concentration.
Figure 3-2 Predicted sy stemic ex posure with secukinumab 30 0mggiven every 2 
weeks or every 4weeksduring maintenance
300mgQ4: secukinumab 30 0mgweekly for 5 weeks (induction), then ever y 4weeks (maintenance)
300mgQ2: secukinumab 30 0mgweekly for 5 weeks (induction), then ever y 2weeks (maintenance)

[COMPANY_001] Confidential Page 21
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Therefore the hypothesis to be tested in this study  is that increasing the exposure to 
secukinumab in subject swith higher weight (i.e. ≥ 90 kg) would result in higher percentage of 
subject s achieving PASI 90 at Week 16.
Risk benefit evaluation of the proposed doses are presented in Section 3.6, Risk and benefits.
3.4 Rationale for choice of comparator
This study  will compare a higher dose regimen (i.e. 300mgevery  2  weeks) which could 
potentially  bring improvement in response while maintaining a favorable safet y profile versus 
secukinumab 300 every  4weeks , which is the approved dose regimen for psoriasis patients . 
3.5 Purpose and timing of primary  endpoint analy sis/design 
adaptations
A primary  endpoint analysis (PEA) may be conducted when all subjects have completed the 
Week 16visit at which the primary  endpoint is assessed. Additional analyses may be 
performed to support health authority  interactions as necessary .
3.6 Risks and benefits 
Secukinumab (Cosent yx) with a recommended dose of 300mgevery  [ADDRESS_148478] not shown any 
impediment to using secukinumab subcutaneously  in human. As of 25 Jun 2017, over 11,000 
patients and healthy  volunteers received secukinumab treatment in [COMPANY_001] sponsored 
investigational clinical studies , including approximately  5,865 patients with moderate to 
severe plaque psoriasis. 
In adult studies, 
secukinumab has shown an excellent efficacy  profile in the treatment of 
moderate to severe chronic plaque psoriasis. Superiority  of secukinumab 300mgto placebo 
was demonstrated for the co -primary  efficacy  criteria of PASI 75 and IGA mod 20 11 0 or 1 at 
12 weeks in all 4 pi[INVESTIGATOR_41958]
-controlled trials (>62% for PASI  75 and >48% for IGA 
mod 2011 0 or 1). Etanercept and placebo -controlled Studies CAIN457A2302 and 
CAIN457A2303 have shown the superior efficacy  of secukinumab 300mgcompared to 
etanercept and placebo with a rapid onset of action, while Study CAIN457A2317 showed 
superiority  and sustained long-term efficacy  of secukinumab 300mgversus ustekinumab in 
patients with moderate to severe plaque
-type psoriasis.
Potential risks for subjects are as outlined in the approved product labelling. At this time, 
safet y data including (1) AE data, laboratory  parameters, available immunogenicity  data from 
the completed studies, and (2) SAE data from the Phase [ADDRESS_148479] of the infections were non-serious, 

[COMPANY_001] Confidential Page 22
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
mild to moderate in severity , clinicall y easily  manageable and did not lead to treatment 
discontinuation. Cases of neutropenia were uncommon, generall y mild to moderate and 
transient and did not lead to treatment discontinuation, and only a few cases were temporall y 
associated with non -serious infections.
Subjects with pre-existing malignancies within the past [ADDRESS_148480] of secukinumab 
on fertility  and embry o-fetal development, women of child bearing potential (WoCBP) can be 
included in studies with secukinumab, but pregnancy  should be avoided by [CONTACT_131549]. No contraceptive measures are required for males participating in studies with 
secukinumab.
Secukinumab 300mgs.c. every  2  weeks was administered in 5completed studies. For two of 
these studies (CAIN457 C2302 and CAIN457 A2208 ) the number of subject s was low (<10) 
and therefore these are not further discussed here.
Patients with uveitis received secukinumab 300mgs.c. every 2 weeks for up to 50 weeks in 
Study CAIN457 C2301/C2301E1 and up to 44 weeks in Study CAIN457 C2303/2303E1 .
Table 3-1 Exposure to 30 0mgs.c. eve ry 2 weeks in completed trials
Study (Indication) Average weight (kg) Number of subject s exposed for:
Any duration 6 months 1 year
CAIN457 C2301& 
CAIN457C 2301E1 (Uveitis)79.4 29 21 4
CAIN457 C2303& 
CAIN457C 2303E1 (Uveitis)69.8 39 34 0
In Study  CAIN457 C2301/C2301E1, the overall number of subject s with an adverse event was 
similar between subject s who received secukinumab 300mgevery  2  weeks versus those who 
received placebo at the same frequency  (82.8% versus 84.8% respectively ), while in Study
CAIN457 C2303/2303E1 , the overall frequency  of AE was higher in the secukinumab 30 0mg
every  2  w eeks group compared to placebo (82.1% versus 74.4% respectively ). Long-term 
treatment with more frequent s.c. doses of secukinumab (300mgevery  2  w eeks) was 
associated with a numerical increase in infections, mainly  due to more reports of non-serious 
nasophary
ngitis , influenza, and upper respi[INVESTIGATOR_131526]. The sample 
size for the secukinumab 300mgevery  [ADDRESS_148481] therefore be done with caution.
Secukinumab 300mgs.c. every  2  weeks was also administered in one ongoing study  for 
which the results are available. Study  CAIN457ADE04 is a randomized, double blind, 
multicenter study  to assess the efficacy  and safety  of 16 weeks secukinumab dosage interval 
shortening (2 weekl y 30
0mgs.c.) in comparison to continued standard treatment (4 weekl y 
300mgs.c.) in patients with moderate severe plaque type psoriasis who achieved less than 
clear or almost clear skin (PASI response greater than or equal to 75 to PASI  less than 90) 
after [ADDRESS_148482] s were enrolled 

[COMPANY_001] Confidential Page 23
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
into the selection phase of the study , then [ADDRESS_148483] s were randomized to either 
secukinumab every  4 weeks (N=162) or every  2 weeks (N= 163). 
Within the randomized subject s, there was a lower incidence rate of AEs in the 300 every  2 
weeks arm compared to the 300mgevery  4 weeksarm (12.9% and 16.7%, respectivel y).The 
majority  of the AEs were from the SOC infections and infestations (10.5%), with mild or 
moderate nasophary ngitis as the primary  contributor (3.1%). An increase in candida infection 
rate was observed in the 300mgevery  2 weeks arm (3.1%) as compared to the 300mgevery 
4weeks arm (1.2%). Serious adverse events occurred at comparable rates to other 
secukinumab studies. SAEs occurred less frequently  in the 300mgevery 2 weeks arm, and 
were also less often related in this arm than in the 30 0mgevery  4 weeks arm (2.5% and 4.9%, 
respectivel y). The most common SOC was infections and infestations (1.2%); 4 of the 5 
reported serious infections were assessed as related to study  treatment. AEs and SAEs lead to 
permanent discontinuation of study  treatment in the 300mgevery  4 weeks only (0.9%), and 
to interruption of study  treatment less frequentl y in the 300mgevery  2  weeks arm than in the 
300mgevery  4 weeks arm (0.6% and 2.5%, respectively ). Results from this study  showed no 
unexpected safet y signals in the safet y profile of secukinumab at both doses regimens . 
[ADDRESS_148484] of a representative group of adult male and female subjects 
(≥ 18 years old) with moderate to severe chronic plaque -type psoriasis of body  weight of
≥ 90 kg at randomization. It is aimed to randomize a total of approximately  330 subjects in 
approximately  100 study sites worldwide. Approximately  472 subjects (30% projected screen 
failure rate) are expected to be screened to provide the number of randomized subjects. 
Subjects who drop out after they  have been randomized will not be replaced.
4.[ADDRESS_148485] fulfill all of the following criteria:
1. Written informed consent must be obtained before any  assessment is performed. Where 
relevant, a legal representative will also sign the informed stud y consent according to 
local laws and regulations.
2.Subjects must be able to understand and communicate with the investigator and comply  
with the requirements of the study .
3.Men or women at least 18 y ears of age at time of screening.
4.Body weight of ≥ [ADDRESS_148486] 6 months and diagnosed before 
randomization.
6.Moderate to severe psoriasis as defined at randomization by :
PASI  score of 12 or greater, and
IGA mod 2011 score of 3 or greater (based on a static scale of 0 –4), and
Body Surface Area affected by  [CONTACT_109010] -type psoriasis of 10% or greater.
7.Candidate for s ystemic therapy . This is defined as a subject having moderate to severe 
chronic plaque -type psoriasis that is inadequatel y controlled by :

[CONTACT_18619] 24
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
topi[INVESTIGATOR_131525]/or,
phototherap y and/or,
previous sy stemic therapy .
4.[ADDRESS_148487] has returned to 
baseline, whichever is longer; or longer if required by  [CONTACT_427].
2.History  of hypersensitivity  to any  of the study  drug constituent s.
3.Forms of psoriasis other than chronic plaque -type (e.g., pustular, ery throdermic and 
guttate psoriasis) at screening or Randomization.
4.Drug -induced psoriasis (i.e., new onset or current exacerbation from beta -blockers, 
calci um channel inhibitors or lithium) at Randomization.
5. Ongoing use of prohibited treatments. Washout pe riods detailed in the protocol have to be 
adhered to ( Table 5 -1).Subjects not willing to limit UV light exposure (e.g., sunbathing 
and / or the use of tanning devices) during the course of the stud y will be considered not 
eligible for this study  since UV light exposure is prohibited.
Note: administration of live vaccines 6 weeks prior to Randomization or du
ring the stud y 
period is also prohibited. 
6.Previous exposure to secukinumab (AIN457) or any  other biologic drug directl y targeting 
IL-17 or the IL -17 receptor.
7.Pregnant or nursing (lactating) women
8.Women of child-bearing potential (WoCBP) , defined as all women ph ysiologically  
capable of becoming pregnant, unless they are using basic methods of contraception 
during the entire stud y or longer if required b y locally approved prescribing information 
(e.g. in EU 20 weeks).
Basic contraception methods include:
Total abstinence (w hen this is in line with the preferred and usual lifest yle of the subject. 
Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation methods) 
and withdrawal are not acceptable methods of contraception.
Female steriliz ation (have had surgical bilateral oophorectom y [with or without 
hysterectom y], total hy sterectom y or tubal ligation at least six weeks before taking stud y 
treatment ). In case of oophorectom y alone, onl y when the reproductive status of the 
woman has been c onfirmed by  [CONTACT_6492] -uphormone level assessment.
Male sterilization (at least 6 months prior to screening). The vasectomized male partner 
should be the sole partner for that subject.
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or ce rvical/vault 
caps). For U nited Kingdom : with spermicidal foam/gel/film/cream/vaginal suppository . 

[COMPANY_001] Confidential Page 25
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Use of oral (estrogen and progesterone) , injected or implanted hormonal methods of
contraception or other forms of hormonal contraception that have comparabl e efficacy
(failure rate <1%), for example hormone vaginal ring or transdermal hormone
contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS).
Incase of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a
minimum of [ADDRESS_148488] y and will be described in the informed consent form (ICF) .
Note: Women are considered post-menopausal and not of child bearing potential if they
have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical
profile (e.g. age appropriate, history  of vasomotor symptoms) or have had surgical
bilateral oophorectom y (with or without hysterectom y), total hysterectomy or tubal
ligation at least six weeks ago. In the case of oophorectom y alone, only when the
reproductive status of the woman has been confirmed by [CONTACT_6492] -
uphormone level
assessment is she con sidered not of child bearing potential.
9.Active ongoing inflammatory  diseases other than psoriasis that might confound the
evaluation of the benefit of secukinumab therap y. Also, underly ing conditions (including,
but not limited to metabolic, hematologic, renal, hepatic, pulmonary , neurologic,
endocrine, cardiac, infectious or gastrointestinal) which in the opi[INVESTIGATOR_131527] y immunocompromises the subject and/or places the subject at unacceptable
risk for receiving an immunomodulatory therapy . In addition, current severe progressive
or uncontrolled diseases which renders the subject unsuitable for the trial or puts the
subject at increased risk, including any medical or psy chiatric condition which, in the
Investigator’s opi[INVESTIGATOR_1649], would preclude the participant from adhering to the protocol or
completing the stud y per protocol.
10.Presence of i nvestigator identified significant medical problems which at investigator's
discretion will prevent the subject from participating the stud y, includin g but not limited
to the following:
Subjects with severel y reduced kidney  function (estimated glomerular filtration rate
(eGFR) ≤29 ml/min/1.73m 2)
11.Chest X -ray, computerized tomography  (CT scan), or 
Magnetic resonance imaging (MRI)
with evidence of ongoing infectious or malignant process, obtained within [ADDRESS_148489] two weeks (exception: common cold) prior to
randomization or any  infection that reoccurs o n a regular basis.
13.History  of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis
infection as defined b y a positive QuantiFERON TB -Gold test (QFT) at screening.
Subjects with a positive or indeterminate QFT test may participat e in the study  if full
tuberculosis work up (according to local practice/guidelines) was completed within [ADDRESS_148490] been initiated and maintained according to local guidelines prior to randomization.

[COMPANY_001] Confidential Page 26
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
14.Past medical history  record of infection with human immunodeficiency  virus (HIV ) , 
hepatitis B or hepatitis C prior to Randomization.
15.History  of lymphoproliferative disease or an y known malignancy  or history  of malignancy  
of an y organ s ystem treated or untreated within the past 5 y ears, regardless of whether 
there is evidence of local recurrence or metastases (except for skin Bowen’ s disease, or 
basal cell carcinoma or actinic keratoses that have been treated with no evidence of 
recurrence in the past 12 weeks; carcinoma in situ of the cervix or non -invasive malignant 
colon poly ps that have been removed).
16.Inability  or unwillingness t o undergo repeated venipuncture (e.g., because of poor 
tolerability  or lack of access to veins). 
17.History  or evidence of ongoing alcohol or drug abuse, within the last six months before 
Randomization.
5 Treatment
5.1 Stud y treatment
5.1.1 Investigational and control drugs
[COMPANY_001] will supply  the investigational therapy
 as follows: 
Secukinumab 150 mgsolution for sub-cutaneous injection in a 1 ml pre -filled sy ringe
Placebo solution for sub-cutaneous injection in a 1 ml pre -filled s yringe
Each Secukinumab placebo pre-filled syringe contains a mixture of inactive excipi[INVESTIGATOR_840], 
matching the composition and the appearance of the secukinumab 150 mgdose.
5.1.2 Additional treatment
No additional treatment beyond investigational drug and control drug are included in this trial.
5.2 Treatment arms
At Baseline /Randomization visit, all eligible subjects will be randomized via Interactive 
Response Technology  (IRT) using a 1:1 ratio to one of the treatment groups:
Secukinumab 300 mgevery 2 weeks group : subjects will receive 2 inj ections of 
secukinumab 15 0mgonce weekl y for four weeks (at Randomization, Weeks 1, 2, and 3), 
followed b y 2 injections of secukinumab 15 0mgevery  two weeks, starting at Week 4 and 
up to Week 48.
Secukinumab 300 mgevery 4weeks group : subjects will rece ive 2 injections of 
secukinumab 15 0mgonce weekl y for four weeks (at Randomization, Weeks 1, 2, and 3), 
followed b y 2 injections of secukinumab 15 0mgevery  four weeks, starting at Week 4 and 
up to Week 12. I n order to maintain the treatment blind, subjec ts will also receive 2 
injections of secukinumab placebo every  4 weeks starting at Week 6, until Week 14.
 

[COMPANY_001] Confidential Page 27
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
 
 
 
 
 
 
 
See Figure 3-1 for graphical representation of t ype of injection per treatment group and visit.
5.3 Treatment assignment and randomization
The investig ator or his/her delegate will contact [CONTACT_131550]/exclusion criteria. The IRT will assign a randomization number to the 
subject , which will be used to link the subject to a treatment arm and will specify a unique 
medication number for the package of study  drug to be dispensed to the subject .The 
randomization number will not be communicated to the caller.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. A patient 
randomization list will be produced by [CONTACT_6609] a validate d system that 
automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication list will be produced by [CONTACT_105240] y Management using a validated system that automates 
the random assignment of medication numbers to packs containing the investigational drug(s). 
Randomization will not be stratified.
The randomization scheme for subjects will be reviewed and approved by a m ember of the 
Randomization Group.
5.4 Treatment blinding
Subjects, investigator staff andpersons performing the assessments , and data analy stswill 
remain blind to the identity  of the study  treatment from the time of randomization until the 
end of study  database lock, using the following methods:
1.Randomization data are kept strictly  confidential until the time of unblinding, and will not 
be acce ssible by  [CONTACT_131551]:
Specific vendors whose role in trial conduct requires their unblinding (e.g., IRT)
Drug Supply  Management

[COMPANY_001] Confidential Page 28
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
The designated [COMPANY_001] study team members involved in the primary  endpoint
analysis, as described in Section 5.4.1
2.The identity  of the treatments will be concealed by [CONTACT_131552], labeling, schedule of administration , appearance, taste 
and odor.
Unblinding will only occur in the case of patient emergencies (see Section 5.6), at the time of 
the primary  endpoint analy sis after all patients have complete d 
Week 16(see Section 5.4.1) 
and at the conclusion of the study . The appropriate personnel from the study  site and [COMPANY_001] 
will assess whether the study  treatment should be discontinued for any subject whose 
treatment code has been broken inadvertently  for any  reason (see Section 5.5.9 ). 
 
5.4.[ADDRESS_148491] completed Week 16 , a small 
selected group of team members (e.g. biostatisticians and programmers involved in the 
analysis, Medical Lead ) may have access to the unblinded results. Subjects and site personnel 
directly  involved in the conduct of the trial, i.e. investigator staff and persons performing the 
assessments ,will remain blinded until the conclusion of the study  to ensure study  integrity  is 
maintained . 
5.[ADDRESS_148492] is assigned the next sequential number 
available in electronic data capture (EDC) system. The investigator or his/her staff will 
contact [CONTACT_131553]. The site must select the case report form (CRF )book with a matching 
Subject Number in the EDC sy stem to enter data. 
If the subject fails to be treated for any  reason, the IRT must be notified within [ADDRESS_148493] was not treated. The reason for not being treated will be entered on the appropriate 
CRF. 
5.5.2 Dispensing the study drug 
Each stud y site will be supplied with study  drug in packaging of identical appearance.
The study  drug packaging has a 2-part label. A unique randomization number is printed on 
each part of this label which corresponds to one of the 2treatment arms and a specific visit. 

[COMPANY_001] Confidential Page 29
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Investigator staff will identify  the study  drug package(s) to dispense to the subject by 
[CONTACT_105245](s). Immediatel y before dispensing 
the package to the subject , investigator staff will detach the outer part of the label from the 
packaging and affix it to the source document (Drug Label Form) for that subject ’s unique 
subject number. 
5.5.3 Handling of study  and additional treatment 
[IP_ADDRESS] Handling of study  treatment 
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and 
designees have access. Upon receipt, all study  treatment must be stored according to the 
instructions specified on the labels. Clinical supplies are to be dispensed only in accordance 
with the protocol. Technical complaints are to be reported to the respective [COMPANY_001] Country 
Pharma Organization Quality  Assurance.
Medication labels will be in the local language and comply  with the legal requirements of 
each country . They  will include storage conditions forthe study  treatment but no information 
about the subject except for the medication number .
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
[CONTACT_18609]. The subjects will 
record the date(s) of administration at home on a diary  and will return the used medication 
and packaging at their next visit to the site. Subjects will be asked to return all unused 
medication and packaging the latest at the completion of the study  or at the time of 
discontinuation of the investigational treatment . Site staff will record in the appropriate 
documents the dates of the administra tion. Detailed instructions will be provided separatel y. 
Patients/subjects will be asked to return all unused study  treatment and packaging at the end 
of the study  or at the time of discontinuation of study  treatment. 
At the conclusion of the study , and as appropriate during the course of the study , the 
investigator will return all unused study  treatment, packaging, drug labels, and a copy of the 
completed drug accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided 
in the investiga tor folder at each site.
[IP_ADDRESS] Handling of additional treatment 
Not applicable.

[COMPANY_001] Confidential Page 30
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
5.5.4 Instructions for prescribing and taking study treatment
Secukinumab solution for s.c. injection or placebo secukinumab solution (active or placebo, 
respectivel y) will be provided in pre-filled s yringes (PFS).
Each subject will require one box of sy ringe set ( PFS) per dose throughout the study : 
Twosecukinumab 15 0mgPFS OR
Two secukinumab placebo [ADDRESS_148494] study  treatment administration will occur at the Randomization/baseline Visit, after 
all study  scheduled assessments have 
been performed (and inclusion/exclusion criteria 
confirmed) and only after the scheduled blood samples have been drawn . Subjects will be 
asked to record details of the doses administered at home on a diary  that will be returned to 
the sites at site visits for review and data capture by [CONTACT_779].
Prior to administration the boxes containing the PFSswith study  treatment solution should be 
allowed to come to room temperature unopened before administration. Used PFSsshould be 
disposed immediately  after use in a sharps container ORaccording to the regulatory  needs of 
the respective countries. For details please refer to the pharmacist manual.
The stud y treatment solution must be injected subcutaneously in non -affected areas of the skin. 
If possible, throughout the trial administer the study  treatment to one of the following body 
regions, rotating the injection site from visit to visit: right thigh, left thigh, right stomach, left 
stomach, upper outer arm (when assisted b y attendant).
All dates and times of injections during the stud y must be recorded on the appropriate CRF. 
All kits of study  treatment assigned by  [CONTACT_131554].
Home A dministration
Between study  visits, subject will be expected to perform home administration in order to 
have administration of study  medication every [ADDRESS_148495] or caregiver . 
The following time points are planned for home administrations of study  medication:  Weeks 
6, 10, 14, 18, 22, 26, 30, 34, 36, 38, 42, 44, 46 and 48.
At the randomization/baseline visit the subjects will be instructed by [CONTACT_131555] “Instructions forUse” on how to self-inject via PFS. For subjects willing to 
self-inject, the first administration shoul d be performed under guidance and supervision of a 
site staff member. 

[COMPANY_001] Confidential Page 31
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
If the subject or caregiver is not able/confident to perform home administration, the subject 
will be allowed to return to the site for administration of the medication. However, during
those visits no other assessments will be performed. 
During home administration, subjects are expected to contact [CONTACT_093]/site staff in case 
they are experiencing any  AE/SAEs or have any  concerns.
The investigator must promote compliance by [CONTACT_131556] y as prescribed and by [CONTACT_131557] ’s 
safet y and the validity  of the study . The subject must also be instructed to contact [CONTACT_121942]/she is unable f or any  reason to take the study  treatment as prescribed.
5.5.5 Permitted dose adjustments and interruptions of study  treatment
Investigational or other treatment dose adjustments and/or interruptions are not permitted.
However, for patients who are unable to tolerate the protocol -specified dosing scheme, a dose 
interruption of investigational drug is permitted in order to keep the patient on study  drug. A 
maximum of one dose may  be missed during each period.
Dosing can be brought forward or delay ed by [CONTACT_8622] 1 week. The subsequent dose should be 
given according to the original schedule (i.e., do not move subsequent dose dates).
These changes must be recorded on the appropriate CRF.
5.5.[ADDRESS_148496] to notify  the study  site about any new medications 
taken after enrolling inthe study . All medications, procedures and significant non-drug 
therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) administered after the subject
was enrolled into the study  must be recorded on the appropriate CRF.
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt the investigator should contact [CONTACT_18614] a subject or allowing a new medication to be started.
5.5.[ADDRESS_148497] 
to notify  the study  site about any new treatments 
he/she takes after the start of the study  treatment. All prohibited medications and significant 
non-drug therapi[INVESTIGATOR_131528] .

[COMPANY_001] Confidential Page 32
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
If a prohibited treatment listed in Table 5-1was used during the study , the subject should 
discontinue use of the prohibited treatme nt if he/she wishes to continue in the study . At the 
discretion of the investigator, if the subject’s use during the study  of a prohibited treatment 
listed in Table 5-[ADDRESS_148498] discontinue study  treatment.
During the screening period, subjects will be allowed to use some active topi[INVESTIGATOR_121884]: face, scalp, and genitoanal area. The active 
topi[INVESTIGATOR_121885]: mild or moderate potency  corticosteroi d (CS) . The subject 
must stop use of these topi[INVESTIGATOR_121886] 12 hours preceding the Randomization visit.
For all other body  regions, a washout period of 2 weeks applies for all active topi[INVESTIGATOR_131529] y indication ( Table 5
-1).
Table 5-1 Prohibited medication
Prohibited treatments1, 2 Washout 
period 
(before 
randomization)Note
1If a prohibited treatment of psoriasis is used during the 
study, the subject should discontinue use of the 
prohibited treatment if he/she wishes to continue in the 
study. 
[ADDRESS_148499] 
should discontinue study treatment at the discretion of 
the investigator. 
Alefacept, briakinumab, 
efalizumab, ustekinumab24weeks
Biological immunomodulating 
agents other than above 
(e.g., adalimumab, etanercept, 
infliximab)12 weeks 
Other systemic immunomodulating 
treatments
(e.g., Methotrexate, cyclosporine A, 
corticosteroids, cyclophosphamide) 4weeks
Other systemic psoriasis 
treatments (e.g. retinoids, 
fumarates, apremilast)4weeks
Photochemotherapy (e.g., psoralen 
and ultraviolet A ( PUVA )) 4weeks
Phototherapy (e.g., UVA, UVB) [ADDRESS_148500] signs and symptoms of
psoriasis (e.g., corticosteroids [CS], 
vitamin D analogues, 
pi[INVESTIGATOR_031], tacrolimus, retinoids, 
salicylvaseline, salicylic acid, lactic 
acid, tar, urea, -hydroxy or fruit 
acids)2 weeks 3Including intra- articular or peri-articular injections. Note 
that inhaled corticosteroids as well as corticosteroid 
drops in the eye or ear or nasal sprays are permitted. 
4 Mild to moderate topi[INVESTIGATOR_131530], 
scalp, hands and feet and/or genitoanal area and if not 
used during the 12 h preceding the ran domization visit.
5 Topi[INVESTIGATOR_131531] 2 only if (all must 
apply):

[COMPANY_001] Confidential Page 33
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Prohibited treatments1, 2 Washout 
period 
(before 
randomization)Note
1If a prohibited treatment of psoriasis is used during the 
study, the subject should discontinue use of the 
prohibited treatment if he/she wishes to continue in the 
study. 
[ADDRESS_148501] 
should discontinue study treatment at the discretion of 
the investigator. 
•medication was started after the Week16visit was 
completed;
•medication was used for 14 consecutive calendar day s 
or less;
•medication was used for an indication other than 
psoriasis and not on the area affected with 
psoriasis.
Live vaccinations66 weeks [ADDRESS_148502] discontinue study treatment.
Any investigational treatment or 
participation in any interventional 
trial4weeks or 5 
half-lives 
(whichever is 
longer) 
There is no restriction on the use of anti- histamines and on the use of topi[INVESTIGATOR_131532] e, nose or ear.
Exposure to light
Subjects need to be advised to limit exposure to UV light (including sunbathing and/or use of 
UV tanning devices) during the stud y to avoid possible effect on psoriasis.
5.5.[ADDRESS_148503] , he/she must provide 
the requested subject identify ing information andconfirm the necessity  to break the treatment 
code for the subject . The investigator will then receive details of the investigational drug 
treatment for the specified subject and a fax or email confirming this information. The sy stem 
will automatically  inform the [COMPANY_001] monitor for the site and the Study Team that the code 
has been broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emerg ency . The investigator 
will provide:
protocol number
study  drug name (if available)
patient number

[COMPANY_001] Confidential Page 34
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
In addition, oral and written information to the subject must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency , or when he/she is unavailab le, to ensure that un-
blinding can be performed at an y time. 
5.[ADDRESS_148504] completed the study  when (s)he has completed the last 
visit planned in the p rotocol.
The investigator must provide follow -up medical care for all subjects who are prematurel y 
withdrawn from the study, or must refer them for appropriate ongoing care.
The information to be collected at this follow -upvisit includes concomitant medications, 
adverse events, and survival status.
5.6.[ADDRESS_148505] occurs when study  drug is stopped earlier 
than the protocol planned duration.
Subjects may  voluntaril y discontinue study  treatment for an y reason at an y time. 
The investigator/qualified site staff must discontinue study  treatment for a given subject if, on 
balance, he/she believes that continuation would be detrimental to the subject’s well -being.
If discontinuation occurs for any reason in a treatment period, the investigator/qualified site 
staff must make every  effort to determine the primary  reason for a subject’s discontinuation 
from the study . This information will then be recorded by [CONTACT_131558]/qualified site staff on 
the disposition CRF. The investigator must also contact [CONTACT_37284] ’s 
discontinuation from study  treatment. If study  drug discontinuation occurs because treatment 
code has been broken (emergency  unblinding) ,please refer to Section 5.5.[ADDRESS_148506] be discontinued under the following circumstances: 
Subject wish
Withdrawal of consent
Emergence of the following AEs: AEs that in the judgment of the investigator/qualified 
site staff, taking into account the subject’s overall status, prevent the subject from 
continuing study  treatment (for example sepsis).
Any laboratory  abnormalities that in the judgment of the investigator/qualified site staff, 
and t aking into consideration the subject’s overall status, prevents the subject from 
continuing study  treatment. 
Pregnancy  (see Section 6.5.6 and Section 7.5)
Use of prohibited treatment as per recommendations in Section 5.5.8. 
Any situation in which study  participation might result in a safet y risk to the subject
Emergency  unblinding

[COMPANY_001] Confidential Page 35
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
Subjects discontinued from study  treatment will NOT be considered discontinued from the 
study . The subject should return to the site after discontinuation of study  drug, for an End of 
Treatment (EOT) visit and Follow -up visits (F4 and F8). Assessments detailed in the “End of
Treatment visit” and Follow -up visits (F4 and F8) in Table 6-1should be completed and 
recorded in the CRF. The investigator must determine the primary  reason for the subject’s 
premature discontinuation of study  treatment and record this information on the CRF.
At the time of the study  treatment discontinuation visit, if it has been approximately  [ADDRESS_148507] dose of study  treatment then the assessments described at EOT1 Visit Week 16(for 
early discontinuation during treatment Period 1) or EOT2 Visit Week 52 (for early 
discontinuation during treatment Period 2) should be completed at this visit.
If it has notbeen approximately  [ADDRESS_148508]’s premature 
withdrawal from the study  and record this information on the appropriate CRF of the 
corresponding period . 
See Section [ADDRESS_148509] :
Does not want to participate in the study  anymore
AND
Does not want an y further visits or assessments
AND
Does not want an y further study related contacts
AND
Does not allow anal ysis of alr eady  obtained biologic material
In this situation, the investigator must make every  effort (e.g. telephone, e-mail, letter) to 
determine the primary  reason for the subject ’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_5366] -up.

[COMPANY_001] Confidential Page 36
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject ’s study  withdrawal should be made as detailed inthe 
assessment Table 6-1.
5.6.[ADDRESS_148510] show "due diligence" by 
[CONTACT_762], e.g. dates of 
telephone calls, registered letters, etc. A subject cannot be considered as lost to follow -up 
until the time point of his/her scheduled end of study  visit has passed.
5.6.5 Early  study termination by  [CONTACT_131559] r any  reason. This may  include reasons 
related to the benefit risk assessment of participating in the study , practical reasons, or for 
regulatory  or medical reasons (including slow enrol lment). Should this be necessary , the 
subject must be seen as soon as possible and treated as a prematurel y withdrawn subject . The 
investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the subject ’s interests. The investigator 
will be responsible for informing the Institutional Review Board/Independent Ethics 
Committee (I RBs/IECs) of the early  termination of the trial.
6 Visit schedule and assessments
Table 6-1lists all of the study  visits and indicates with an “X” when the assessments are to be 
performed. An ‘S’ indicates the data for that assessment are in the source documents at the 
site. 
Subjects should be seen for all visits on the designated day or as closely  as possible to the 
original planned visit schedule. 
If for any reason the subject is a screen failure, the subject may be rescreened. There is no 
restriction on the number of times a potential subject may  be rescreened or on how much time 
must pass from t he date of screen failure and the date of rescreening. 
If a subject rescreens for the study , then the subject must sign a new ICF and be issued a new 
subject number prior to any screening assessment being conducted for the subject under the 
new screening subject number. For all rescreened subjects, the investigator/qualified site staff 
will record if the subject was rescreened on the rescreening CRF and the original screening 
number the subject was issued prior to the current screening number.
The date of the new informed consent signature [CONTACT_109061]. Informed Consent for a rescreened subject 
must be obtained prior to performing any study -
related assessment or collecting any data for 
the Screening Visit. For rescreening, all screening assessments must be performed as per 
protocol, except for the tuberculosis (TB) work up, if applicable, if performed not more than 
12 weeks before randomization.

[COMPANY_001] Confidential Page 37
Clinical Tri al Protocol (Version 0 0) Protocol No. C AIN457A2324
If the date of a TB work up is less than [ADDRESS_148511] study  treatment administration, at which time all the assessments listed 
for EOT 1 ( Week 16)/EOT 2 (Week 52) will be performed. Then, subjects should return to the 
study  site for further assessments as indicated under the follow -up visits (F4 and F8). 
If a subject refuses to return for these assessments or are unable to do so, every  effort shou
ld 
be made to contact [CONTACT_18622] a knowledgeable informant by [CONTACT_131560] (i.e. certified letter) immediately . At this contact, the safet y (e.g., 
potential occurrence of AE or SAE) and the primary  reason for a subject’s premature 
withdrawal should be determined.
At a minimum, subjects who pre-maturel y discontinue the treatment will be contact[CONTACT_131561] y evaluations during the [ADDRESS_148512].
Suggested order of assessments:
Suggested guidelines for conduct of the visit assessments are listed below.
Investigator to complete efficacy  assessments:
1.IGA
2.PASI
The PASI  Score and Investigator’s Global Assessment eCRFs must be completed 
prior to contact[CONTACT_131562]. At Randomization, the investigator must 
confirm subject meets IGA mod 2011, PASI and BSA eligibility  before randomizing 
the subject .  
All remaining stud y procedures (e.g. laboratory  sample c ollection, vital signs
measurements, ECG, etc.) must be completed prior to study  treatment dosing
Contact I RT to register the subject visit, as applicable.
Administration of study  treatment, as applicable.

[COMPANY_001] Confidential Page 38
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Table 6-1 Assessment schedul e
Periods Screen Treatment Period 1 Treatment Period 2Unscheduled visit
(a)Post Treatment 
Follow -up 
Period
Week (relative to 
randomization (R))≥-4 to
≤-1R 1 2 3 4 8 12 16
EOT120 24 28 32 40 52
EOT2F4
56F8 
60
Day
Assessment≥-28 to
≤-71 8 15 22 29 57 85 113 141 169 197 225 281 365 393 421
Site visit S S S S S S S S S S S S S S S S S S
Obtain informed consent X
Demographics X
Inclusion/exclusion criteria X X
Smoking history X
Psoriasis medical history / 
previous psoriasis therapi[INVESTIGATOR_131533] X X X X X X X X X X X X X X X X X X
Physical examination S S S S S S S S S
Height X
Weight X X X X X X
Vital signs (blood pressure and
pulse)X X X X X X X X X X X X X X X X X X
R= Randomization; X = assessment to be recorded on clinical database; S = assessment to be recorded on source documentation .
(a)Unscheduled visit: The assessment(s) performed at an unscheduled visit are at the investigator’s discretion .

[COMPANY_001] Confidential Page 39
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Periods Screen Treatment Period 1 Treatment Period 2Unscheduled visit
(a)Post Treatment 
Follow -up 
Period
Week (relative to 
randomization (R))≥-4 to
≤-1R 1 2 3 4 8 12 16
EOT120 24 28 32 40 52
EOT2F4
56F8 
60
Day
Assessment≥-28 to
≤-71 8 15 22 29 57 85 113 141 169 197 225 281 365 393 421
Laboratory sampling: safety 
panel (Clinical chemistry, 
hematology)X X X X X X X X X X X X X X
Fasting labs: glucose, lipid 
panel)X X X X X
QuantiFERON ®TB-Gold In -tube 
testX X X
Serum pregnancy test (WoCBP 
only)X
Urine pregnancy test (local)
(WoCBP only)S S S S S S S S
Urinalysis (local) X X
TB: tuberculosis; X = assessment to be recorded on clinical database; S = assessment to be recorded on source documentation ; WoCBP = women of child bearing potential 
(a) Unscheduled visit: The assessment(s) performed at an unscheduled visit are at the investigator’s discretion .
 

[COMPANY_001] Confidential Page 40
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Periods Screen Treatment Period 1 Treatment Period 2Unscheduled visit
(a)Post Treatment 
Follow -up 
Period
Week (relative to 
randomization (R))≥-4 to
≤-1R 1 2 3 4 8 12 16
EOT120 24 28 32 40 52
EOT2F4
56F8 
60
Day
Assessment≥-28 to
≤-71 8 15 22 29 57 85 113 141 169 197 225 281 365 393 421
ECG (standard 12 -lead) X X X X
Chest X -ray
(optional)S
PASI X X X X X X X X X X X X X X X X X X
IGA mod 2011 X X X X X X X X X X X X X X X X X X
AE/SAE assessment X X X X X X X X X X X X X X X X X X
Contact [CONTACT_12067] S S S S S S S S S S S S S S
Administer study treatment 
during visitX X X X X X X X X X X X X
Review home administration 
diary (c)S S S S S S S S S S
Study Completion Form X
ECG: electrocardiogram; eCRF ;PASI: Psoriasis Area and Severity Index; IGA: Investigator’s Global Assessment; ; AE: adverse event; IRT: interactive 
response technology; 
X = assessment to be recorded on clinical database; S = assessment to be recorded on source documentation    
(a)Unscheduled visit: The assessment(s) performed at an unscheduled visit are at the investigator’s discretion . 
(c)The following time points are planned for home administrations of study medication:  Weeks 6, 10, 14, 18, 22, 26, 30, 34, 36, 38, 42, 44, 46 and 48.

[COMPANY_001] Confidential Page 41
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
6.1 Information to be collected on screening failures 
Subjects who sign the informed consent form and discontinue prior to randomization at 
Visit 2 (Baseline) are considered screening failures.
For each subject who has signed infor med consent and discontinue dbefore entering the 
double -blind treatment period, IRT must be notified within 5 days and the reason for not 
being randomized will be entered on the disposition CRF .  In addition, the Screening visit 
date, the Demog raphy CRF, Informed Consent CRF, Inclusion/Exclusion Criteria CRF and   
Subject rescreening CRF must be completed for rescreened subjects . 
Adverse events that are not SAEs will be followed by [CONTACT_131563]. However, serious adverse events should be recorded in the CRF for any 
serious adverse event (SAEs) that occurred during the screening period. If consent was 
withdrawn during the screening period before the subject was randomized ,complete the 
appropriate CRF . 
6.2 Patient demographics/other baseline characteristics 
6.2.[ADDRESS_148513] demographic data will include: age, sex, race andethnicity .
6.2.2 Psoriasis medical history / p revious psoriasis therapi[INVESTIGATOR_131534] -psoriasis therapi[INVESTIGATOR_014]: 
The date of first diagnosis of plaque -type psoriasis (by  a phy sician).
The previous treatments of psoriasis (including previous use of biologic therapi[INVESTIGATOR_014], as 
well as phototherap y and/or photo- chemotherap y) and the reason for discontinuation.
6.2.3 Smoking history
The current and/or previous use of tobacco products will be recorded, as well as the estimated 
number of pack- years based on the approximate consumption per y ear. 
6.2.4 Co-morbidities –cardiovascular medical history
Any information pertaining to cardiovascular medical history  assessed prior to randomization.
6.2.5 Relevant medical history /current medical conditions
Relevant medical history and current medical conditions present before signing the informed 
consent should be recorded in the CRF capturing medical h istory .
Relevant medical history/current medical condition data includes data up to 6 months prior to 
signing of the informed consent and until the start of study  treatment. Whenever possible, 
diagnoses and not s ymptoms should be recorded.

[COMPANY_001] Confidential Page 42
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Any information pertaining to psoriasis or cardiovascular medical history  assessed prior to 
randomization should be reported.
Chest X -ray (optional)
Chest X-ray is an optional assessment which can beperformed during screening at the 
discretion of the investigator, if warranted for the subjects. This is aimed to detect ongoing 
infection and particularl y tuberculosis or malignancy.
A chest X-ray (or chest MRI  at pre specified sites) must only be done after it is fairly  certain 
that the subject meets the inclusion/exclusion criteria, in order to minimize unnecessary 
exposure to X -ray radiation for subjects.
If the chest X-ray, CT scan, or MRI  evaluated by a qualified physician reveals an evidence of 
untreated infections or malignancies the subject will not be enrolled into the study .
6.2.6 Determination of the tuberculosis status
Determination of the tuberculosis (TB) status will be required before administration of study  
treatment and should be performed as defined by [CONTACT_13144]. The TB status must be 
determined by [CONTACT_9870] , signs, symptoms, TB testing (QuantiFERON -TB Gold assay). 
Any significant findings should be recorded in the TB assessment eCRF and the CRF 
capturing m edical history, as deemed necessary . 
QuantiFERON ®TB-Gold In -Tube assay
A QuantiFERON® TB-Gold In-Tube assay  (QFT) to screen a population for latent 
tuberculosis infection (Doherty  et al 2008) will be used at screening to evalua te the subjects’ 
eligibility  for the study . This 
blood -based assay  is specific for Mycobacterium tuberculosis 
and is not influenced by [CONTACT_37257] -Guérin vaccination or by [CONTACT_131564]. Furthermore, this test, in contrast to the purified protein 
derivative ([COMPANY_003]) skin test, is also insensitive to a booster effect since the subject is not 
exposed to the vaccine . The assay  measures the production of interferon- gamma and presents 
it relative to a negative and a positive control sample (Manuel and Kumar, 2008). The 
QuantiFERON® -TB Gold assay  test will be supplied by [CONTACT_2237] . Details 
on the 
collection, shipment of samples and reporting of results by  [CONTACT_131565] -specific laboratory  manual.
The workflow of sample handling in case of positive or indeterminate test results is provided 
in Figure 6 -1. 
If the test result is negative , the subject may  be randomized.
If the test result is positive , the investigator should perform workup for the test result 
as per local procedures. If a TB workup was conducted prior to the screening the 
subject, results of the wor kup can be used to assess eligibility if the workup was 
conducted within 12 weeks prior to randomization.
Note: Subjects positive for latent TB per workup may be randomized to the trial if 
sufficient treatment has been initiated according to local routine clinical practice and will 
be maintained for the prescribed duration. Subjects positive for active TB per workup are 
not eligible for the study . Subjects negative for TB (no signs of latent or active TB) per 
workup may  be randomized to the trial.

[COMPANY_001] Confidential Page 43
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
If the test result is indeterminate , the investigator may repeat the test once or may
proceed directly to perform workup for the test result as per local procedures. This
action is at the discretion of the investigator. If a TB workup was conducted prior t o
the screening the subject, results of the workup can be used to assess eligibility  if the
workup was conducted within [ADDRESS_148514] positive for latent TB per workup may  be
randomized to the trial if sufficient treatment has been initiated according to
local routine clinical practice and will be maintained for the prescribed
duration. Subjects positive for active TB per workup are not eligible for the
study. Subjects negative for TB per workup (no signs of latent or active TB)
may be randomized to the trial.
oIf the second test is again indeterminate , the investigator should perform
follow -up for the test result as per local procedures. Subjects tested posi tive for
latent TB per workup may  be randomized to the trial if sufficient treatment has
been initiated according to local routine clinical practice. Subjects positive for
active TB per workup are not eligible for the study. Subjects negative for TB
per wo rkup (no signs of latent or active TB) may  be randomized to the trial if
the workup was conducted within 12 weeks prior to randomization.
Note: i f eligibility  is being assessed with only  [ADDRESS_148515] result and a TB workup (i.e., no 
second TB test will be perfor med), the TB test to assess eligibility  must have been done 
via the central laboratory for the stud y within the screening period (within 4weeks prior 
to randomization) and TB workup will onl y be considered if it was completed within [ADDRESS_148516] positive for latent TB per workup may  be 
randomized to the trial if sufficient treatment has been initiated according to local routine 
clinical practice and will be maintained for the prescribed duration. Subjects positive for
active TB per workup are not eligible for the study. Subjects negative for TB per workup 
(no signs of latent or active TB) may  be randomized to the trial

[COMPANY_001] Confidential Page 44
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Figure 6 -1 Tuberculosis screening flowchart
6.2.7 Other ba seline char acteristics
Baseline char acteristic data to be co llectedonthose indicated with an “X” in Table 6-1
for the screening and randomization visit. 

[COMPANY_001] Confidential Page 45
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
6.[ADDRESS_148517] ugLabel Form information and information co ll ectedby[CONTACT_12067].
6.4 Efficacy
The foll owingordershould b e applied when performing the effic acy assessments at study 
visits:
I
nvesti gat or’s Global A sse ssment for general psoriasis (IGAm od 2011; scale from 0-4)
P
soriasis Ar eaand Severity Index (PASI; score from 0 – 72)
6.4.1 Investigator Global Assessment (IGA  mod 2011)
IGAmod [ADDRESS_148518] udy whenever 
possible.
I
n collaboration with health authorities, in particul arthe FDA, the I GAmod 2011 scale (s ee 
Table 6-2) has been develo pedb ased on a pr evious version o f the scale us edin secukinuma b 
Phase 2
studies. The only chan gef rom the Phase 2 scale to Phase 3 scale was to con dense 
the very severe and severe subj ects into one category “sever e”. The explanations/description s 
of the points on the scale have been improv edt o ensure appr opriate di fferentiation bet ween 
them.
The I GAmod [ADDRESS_148519]’s dis ease 
state at the t ime of the asse ssments, and does not attempt a comparison with a nyof th e 
subject’s pr evi ous disease states, whether at base line or at a pr evious visit.
T
he IGAmod [ADDRESS_148520] clearNormal to pi[INVESTIGATOR_108997]; no thickening; no to minimal 
focal scaling.
2 MildPi[INVESTIGATOR_22767]; just detectable to mild thickening; 
predominantly fine scaling.
3 ModerateDull bright red, clearly distinguishable erythema; clearly 
distinguishable to moderate thickening; moderate scaling.
4 SevereBright to deep dark red coloration; severe thickening with hard 
edges; severe / coarse scaling covering almost all or all lesions.
Note: Involvement of nails is not part of the assessment.

[COMPANY_001] Confidential Page 46
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Based on this scale, a subject will be eligible to participate in the study  if the subject has an 
IGA mod 2011 score at baseline (Visit 2) of [ADDRESS_148521] 2 points on the IGA scale 
compared to baseline.
6.4.2 Assessment of total Body surface A reaand Psoriasis A rea Severity 
Index
The investigator or trained qualified designee will complete the PASI  assessment as indicated 
in Table 6-1. Whenever possible, the same evaluator should perform this PASI  assessment at 
all visits.
The total BSA affected by [CONTACT_109010] -type psoriasis will be estimated from the percentages of 
areas affected, including head, trunk, upper limbs and lower limbs (see below for PASI 
assessment) . The following calculations will be done: Each reported percentage will be 
multiplied by [CONTACT_121958] (head = 0.1, trunk = 0.3, upper 
limbs = 0.2, lower limbs = 0.4). The resulting 4 percentages will be added up to estimate the 
total BSA affected by [CONTACT_109010] -type psoriasis . The PASI  scoring system is further described in 
Table 6-3.
A PASI  score (Fredriksson and Pettersson 1978 , Weisman et al 2003 , Gottlieb et al 2005) will 
be derived as indicated in Table 6 -
3. The head, trunk, upper limbs and lower limbs are assessed 
separatel y for erythema, thickening (plaque elevation, induration), and scaling (desquamation) .
The average degree of severit y of each sign in each of the four body  regions is assigned a score 
of 0-4. The area covered by  [CONTACT_131566] a percentage of the total 
area of that particular body  region . Further practical detai ls help the assessment:
1.The neck is assessed as part of the head.
2.
The axillae and groin are assessed as part of the trunk.
3.The buttocks are assessed as part of the lower limbs.
When scoring the severity  of ery thema, scales should not be removed.
Table 6-3 The PASI scoring sy stem
Body region Erythema (E) Thickening (plaque 
elevation, 
induration, I)Scaling 
(desquamation, D)Area score
(based on true 
area %, A )*
Head (H)† 0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=no 
involvement
1=>0 -<10%
2=10 -<30%
3=30 -<50%
4=50 -<70%
5=70 -<90%
6=90 -100%
Trunk (T)‡ 0=none 
1=slight 
2=moderate 
3=severe0=none 
1=slight 
2=moderate 
3=severe0=none 
1=slight 
2=moderate 
3=severe0=no 
involvement
1=>0 -<10%
2=10 -<30%

[COMPANY_001] Confidential Page 47
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
4=very severe 4=very severe 4=very severe 3=30 -<50%
4=50 -<70%
5=70 -<90%
6=90 -100%
Upper limbs 
(U)0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=no 
involvement
1=>0 -<10%
2=10 -<30%
3=30 -<50%
4=50 -<70%
5=70 -<90%
6=90 -100%
Lower limbs 
(L)§0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=no 
involvement
1=>0 -<10%
2=10 -<30%
3=30 -<50%
4=50 -<70%
5=70 -<90%
6=90 -100%
*Percentage (not score) of body region (not whole body) affected will be entered in the CRF
†Neck is assessed as part of the Head (H) body region.
‡Axillae and groin are assessed as part of the Trunk (T) body region.
§Buttocks are assessed as part of the Lower limbs (L) body region. 
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately  
10%, 20%, 30% and 40% of the body  surface area, respectively , the PASI score is calculated 
using the formula:
PASI  = 0.1(EH+ IH+ D H) AH+ 0.2(EU+ IU+ D U) A U + 0.3(ET+ IT+ D T) A T + 0.4(EL+ IL+
DL) A L
The key s for the letters are provided in Table [ADDRESS_148522] will be consi dered as a P ASI 90 resp onderif s/heachieves a reduction of 90% or
more of the PASI scor e,compar edtobaseline, ata given t ime point.
During the study , at each visit, the PASI  score will be calculated and response will be 
classified according to the definitions from Committee for Medicinal Products for Human Use 
(CHMP) guidelines for psoriasis CHMP/EWP/2454/ 02 2004 .

[COMPANY_001] Confidential Page 48
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
 
 
 
 
PASI 90 response: subjects achieving ≥ 90% improvement (reduction) in PASI  score 
compared to baseline 
I
n addition to the a ss essment of PASI, the investigator will a ssesswhether new pustu lar 
psoriasis, or new erythroder mic psoriasis, or more infla mma tory psoriasis o ccurred (yes/no).
6.4.[ADDRESS_148523]’s body  area is affected by [CONTACT_90050], is considered acceptable by [CONTACT_19397] (CHMP/EWP/2454/02 2004) to assess efficacy  in conjunction with Investigator’s 
Global Assessment mod 2011 (IGA mod 2011).
6.[ADDRESS_148524] aws and safety asse ssments should be done prior tostudy trea tmen t 
administration. Appropriate safet y assessments (e.g., evaluation of AEs and SAEs includi ng 
injectio
n site r eactions) sh ou ld be repeatedafter the dose is administer ed.
E
valuation of all AEs and SAE s including inj ect ion site hypersensitivity reactions, v ital 
signs, laboratory asse ss ments and o ccurrence of inf ections.
Physi cal examination
Vital signs
Height and weight
Laboratory evaluation s (He ma tology, Clinical chemistr y, Urinalysis)
ECG
Pregnancy and assessments of fertility

[COMPANY_001] Confidential Page 49
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
6.5.1 Physical examination
A physical examination, including general appearance, skin, neck, eyes, ears, nose, throat, 
lungs, heart, abdomen, back, l ymph nodes, extremities, vascular and neurological s ystems will 
be performed as indicated in Table 6-1.
If indicated, based on medical history  and/or symptoms, additional exams will be performed 
at the discretion of the investigator.
Whenever possible, assessments for an individual subject should be performed by [CONTACT_37269] y site staff throughout the study.
Information for all phy sical examinations must be included in the source documentation at the 
study  site. Significant findings that are present prior to the start of the study , i.e. all findings 
prior to signing the informed 
consent form (ICF), must be included in the CRF capturing
Medical History . Significant findings after enrollment into the study  that meets the definition 
of an adverse event must be recorded on the CRF capturing Adverse Event .
6.5.2 Vital signs 
Vital signs ( includi ngb l ood pre ssure and pulse m easurements) w ill b e assessed at ever y 
scheduled visit asi ndi catedinTable 6-1. Whenever possib le, asse ssments sh ould be
performed by[CONTACT_131567] t the stud y.
After the subj ecth as been sitting for about five minutes, with b acksupport edand both fe et
placed o n the fl oor, systo lic and dias tolicblood pre ssure w ill be measu red twice and will
be recorded in the sour ced ocumentation (measurements separated by1to 2mi nutes)
using a v alidated device,with anappropriatel y s i zedcuff ( Mancia et al 2007). In ca se the
cuff size s available are not large enough for the subject’s arm circumferen ce, a
s
phygmomanomet er with an appropriately sized cuff may be us ed.T he aver ageof the two
measurements will be entered on the CRF capturing Vital Signs . 
Normal blood pressure will be defined as a systolic pressure of 90 to < 120mmHg, and a 
diastolic blood pressure of 60 to < 80 mmHg under measurement conditions as outlined above. 
Notable blood pressure will be hypertension (systolic ≥ 140 mmHg and/or diastolic ≥ 90 
mmHg) or hypotension (systo lic < 90 mm Hgand/or diasto li c < 60 mmHg). A blood 
pressure indicative of pre-hypertension (systolic 120 to <140 mmHg and/or diastolic 80 to < 
90 mmHg) will not be regarded as notable ( Chobanian et al 2003) .
A norma l pulse rate w ill be d efined as a rate of 60 to 100 b ea ts per minute under th e 
measurement conditio ns o utlined abov e.Notable pulse rates are a rate below 60 bp m 
(
brady cardia)orabove 100bpm (t achycardia).
Nospecificaction is pre-defined within this protocol tor espond tospecific ab normal vita l 
s
igns,asit will be deci dedby[CONTACT_131568] n eeds to b e 
takento respond to any abnormal values, taking into acco unt the overall status of the subj ect.
6.5.3 Height and weight 
Height and b ody weight will be measur ed as listed in Table 6-1.

[COMPANY_001] Confidential Page 50
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Height and b ody weight wi llbe measur edi n indoor clothin g,b ut without shoes. Whenever,
possible, b ody weigh t assessments sh ould b e performed by [CONTACT_131569]; the same scale should be used throughou t the study.
6.5.[ADDRESS_148525].
[IP_ADDRESS] Hematolog y
Hem oglobin, hematocrit, red bl ood cel l count, white bl oodcell (WBC) count with differentia l 
(neutrophils i ncluding bands, lymphocytes, monocytes, eosinophils, basophils) and platel et 
c
ount wi llb e m easur ed at all sc heduled st udy visits, within the visit window suggested
i
n Table 6-1.
[IP_ADDRESS] Clinical chemistry
Ser
um chemistry wi llinclude ur ea,c reatini ne,tot al bilirubin, AST (S GO T), ALT (SGPT) , 
Gamma -Glutam yl Transferase (GGT) , alkali nep hosp hatase, s odium, pot assium, bi carbonate,
calcium, phosphorous, tota l protein, albu mi n, amylase, lipase and uric acid. Ser um
chemistry w illbe measur ed at all sched uled stud y v isits with in the visit wind ow specified
inTable 6-1.
[IP_ADDRESS] Fasting Laboratory  evaluations
Fasting (8 hour duration with water ad libitum ) laboratory  evaluations will be assessed as at 
baseline as indicated in Table 6-1. 
[IP_ADDRESS].1 Plasma glucose
Fasting plasma glucose will be taken as a fasting blood sample as indicated in Table 6-1.
[IP_ADDRESS].2 Lipid panel
A lipid profile including High Density  Lipoprotein (HDL), Low Density  Lipoprotein (LDL), 
cholesterol, triglycerides, lipoprotein (a), apolipoprotein B, apolipoprotein A-1, and 
adiponectin will be measured from a fasting blood sample as indicated in Table 6 -1.

[COMPANY_001] Confidential Page 51
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
[IP_ADDRESS] Urinaly sis
Dipsticks will be p rovided t o the st udy sites for local urinalysi s ass essments. The sites
will r ecord the results in the appropriat e C RF for each subject. Standard d ipstick
m
easurement s f or s pecific gr avity, pro tein, glucos e,pH, blood, urine bl ood dipsti ck(non-
hemolyz ed), urine bl ood dipsti ck(hemoly zed) , bilirubin,ketones and WBC wi ll be done as
i
ndicated in Table 6-1.
6.5.5 Electrocardiogram (ECG) 
A standard single 12-leadECG will be ECGs will be measured according to the assessment 
schedule in Table [ADDRESS_148526] be reviewed for major abnormalities prior to dosing. 
Clinically  significant abnormalities should be recorded on the relevant section of the CRF 
capturing 
medical history/ Current medical conditions/AE as appropriate.
6.5.6 Pregnancy  and assessments of fertility  
Pregnancy  tests will be performe d inall women of child- bearing potential (see Section 4.2 for 
definition of child- bearing potential ), asindicatedinTable 6-1. Additional pregnancy  testing 
might be performed if requested b y local requirements.
Any w
oman w
ith a confirmed positive pregnancy test during screeni ngi s not e ligible fo r 
rando mization. A p ositive u rine p regnanc y test during the treatment period s of the stud y 
r
equires immediat e i nterruption of study treatment until a serum β- subunit of human 
chorionic gonadotropin (
β-hCG ) i s performed and f ound tobe negative. I f the serum β-hCG
t
est is positive, the subject must b e d iscontinued from the study  treatment.
 

[COMPANY_001] Confidential Page 52
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324

[COMPANY_001] Confidential Page 53
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324

[COMPANY_001] Confidential Page 54
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
7 Safety  monitoring 
7.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 

[COMPANY_001] Confidential Page 55
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
study  until the end of study  visit. Therefor e, an AE may or may not be temporally  or causall y 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse event irrespective if a clinical even t has occurred.
The occurrence of adverse events must be sought by [CONTACT_105]-directive questioning of the subject
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by [CONTACT_109049], laboratory 
test findings, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms, 
they are considered clinically  significant, 
they require therapy . 
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant 
changes from 
baseline or the previous visit, or values which are considered to be non -typi[INVESTIGATOR_131535]. Investigators have the responsibility  for managing the safet y of individual 
subject and identify ing adverse events. Alert ranges for laboratory  and other test abnormalities 
are included in Appendix [ADDRESS_148527] be recorded in the appropriate CRF capturing Adverse Events under the 
signs, symptoms or diagnosis associated with them, accompan ied by [CONTACT_131570]:
the severit y grade
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
its rela tionship to the study  treatment (suspected: Yes/ No)
its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved must be reported.
whether it constitutes a serious adverse event (SAE -See Section 7.2 for definition of SAE) 
and which seriousness criteria have been met.
action taken regarding study treatment 
All adverse events must be treated appropriately . Treatment may include one or more of 
the following: 
noaction taken ( e.g. further observation only ) 
study treatment dosage increased/reduced
study treatment interrupted/withdrawn
concomitant medication or non- drug therap y given 
subject hospi[INVESTIGATOR_057]/ subject ’s hospi[INVESTIGATOR_18533] (see Section 7.2 for definition of 
SAE)

[COMPANY_001] Confidential Page 56
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
its outcome (not recovered/not resolved; recovered/resolved; recovered/resolved with 
sequelae; fatal; or unknown)
Once an adverse event is detected, it must be followed until its resolution or until it is judged 
to be permanent, and assessment must be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  drug, the interventions 
required to treat it, and th e outcome.
Worsening of psoriasis in this study  is evaluated via 
the use of PASI , IGA mod 2011 and 
 is not expected to be captured as an AE in the CRF capturing adverse 
events . Exceptions include cases when a) a new type of psoriasis isdiagnosed e.g. guttate 
psoriasis or b) the worsening of psoriasis is so severe that a qualitatively  different status is 
reached.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be included in the subject
informed consent and should be discussed with the subject during the study  as needed. Any 
new information regarding the safet y profile of the medicinal product that is identified 
between IB updates will be communicated as appropriate, for example, via an Investigator 
Notification or an Aggregate Safet y Finding. New information might require an update to the 
informed consent and has then to be discussed with the subject .
The investigator must also instruc t each subject to report any new adverse event (beyond the 
protocol observation period) that the subject , or the subject ’s personal physician, believes 
might reasonabl y be related to study  treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to [COMPANY_001].
7.2 Serious adverse events 
7.2.1 Definition of SA E 
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing )]
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the 
following criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify  what this includes)
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting i n hospi[INVESTIGATOR_131536] 57
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
social reasons and respi[INVESTIGATOR_37207] ’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction ; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe ( please refer to Annex I V, ICH -E2D Guideline ).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considere d serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_50068]. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_50069] ( please refer to Annex I V, ICH-E2D Guideline ).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
7.2.[ADDRESS_148528]’s last visit will be reported in the appropriate eCRF. SAEs 
beyond the last visit will only be recorded in the [COMPANY_001] Drug Safety  and Epi[INVESTIGATOR_131537].
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_30755] [ADDRESS_148529] be reported separatel y as a new event.
Inform ation about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess the relationship of each SAE to study treatment, 
complete the SAE Report Form in English, and submit the completed form within 24 hours to 
[COMPANY_001]. Detailed instructions regarding the submission process and requirements for 
signature [CONTACT_131580]. 

[COMPANY_001] Confidential Page 58
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Follow -up information is submitted as instructed in the investigator folder. Each re-
occurrence, complication, or progression of the original event must be reported as a follow -up 
to that event regardless of when it occurs. The follow -up information should describe whether 
the event has resolved or continues, if and how it was treated, whether the blind was broken or 
not, and whether the subject continued or withdrew from study  participation.
If the SAE is not previously  documented in the Invest igator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment a Drug Safet y and 
Epi[INVESTIGATOR_131538]. Nova rtis may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same study  
treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with EU Guidance 2011/C 172/[ADDRESS_148530] safet y and enhance reliability  in de termining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed. 
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study  (irrespective of whether classified/reported as (S)AE)
:
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow -up moni toring should be 
entered into the appropriate CRFs . 
Please refer to Table 13-1 in Appendix 2for complete definitions of liver laboratory  triggers 
and liver events. 
Every  liver laboratory  trigger or liver event as defined in Table 13-1 in Appendix 2should be 
followed up by [CONTACT_121967].
Detailed information is outlined in Table 13
-2in Appendix 2 .
For the liver laboratory  trigger:
Repeating the liver function test (LFT) within the next week to confirm elevation.
These LFT repeats must be performed using the central laboratory  if possible. If this is not 
possible, then the repeats can be performed at a local laboratory  to monitor the safet y of the 
subject . Repeats laboratory  must then be performed at central laboratory  as soon as possible. 
If a liver event is subsequently  reported, any local LFTs previousl y conducted that are
associated with this event must be reported on the appropriate CRFs.
If the elevation is confirmed, close observation of the subject will be initiated, including 
consideration of treatment interruption if deemed appropriate.
For the liver events:

[COMPANY_001] Confidential Page 59
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Repeating the LFT to confirm elevation as appropriate
Discontinuation of the investigational drug if appropriate
Hospi[INVESTIGATOR_131539]
A causalit y assessment of the liver event via exclusion of alternative causes (e.g., disease, 
co-medications)
An investigation of the liver event which needs to be followed until resolution. 
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -upi[INVESTIGATOR_92825], and 
the procedures performed must be recorded on appropriate CRFs.
7.4 Reporting of study  treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicin e while under the control of a healthcare professional, subject or 
consumer ( European Medicines Agency  definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y 
used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  [CONTACT_50104].
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected i n 
appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being associated with an AE/SAE.
Table 7-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error 
typeDocument in 
study 
treatment CRF
(Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with an 
SAE
Misuse/Abuse Yes Yes Yes, even if not associated 
with a SAE
7.[ADDRESS_148531] 
be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should 
be followed up to determine outcome, including spontaneous or voluntary  termination, detai ls 
of the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or newborn complications.
Pregnancy  must be recorded on the Pharmacovigilance Pregnancy  Form and reported by [CONTACT_50105] y and Epi[INVESTIGATOR_18540]. Pregnancy 

[COMPANY_001] Confidential Page 60
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the study  treatment. 
Any SAE experienced during the pregnancy  and unrelated to the pregnancy must be reported 
on a SAE form.
8 Data revie w and database management 
8.1 Site monitoring 
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (i.e. eCRFs) with the 
investigators and their staff. During the study , [COMPANY_001] employ s several methods of ensurin g 
protocol and Good Clinical Practice (GCP) compliance and the quality /integrity  of the sites’ 
data. The field monitor will visit the site to check the completeness of patient records, the 
accuracy  of data capture / data entry , the adherence to the protocol and to Good Clinical 
Practice, the progress of enrollment, and to ensure that study  treatment is being stored, 
dispensed, and accounted for according to specifications. Key study personnel must be 
available to assist the field monitor during these visits . Continuous remote monitoring of each 
site’s data may be performe d by a  c entralized [COMPANY_001] Clinical Research Associates 
organization. Addition ally, a central analyticsorganization may analyze data and identify 
risks and trends for site operational parameters, and provide reports to [COMPANY_001] Clinical 
Teams to assist with trial oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject 's file. The investigator must also keep the original informed consent form signed by 
[CONTACT_423] (a signed copy  is given to the subject ).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards 
require full verification for the presence of informed consent, adherence to the 
inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all 
primary  variables. Additional checks of the consistency  of the source data with the CRFs are 
performed according to the study -specific monitoring plan. No information in source 
documents about the identity  of the subjects will be disclosed.
8.2 Data collection
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRFs) using fully  validated secure web-enabled software that conforms 
to US CFR [ADDRESS_148532] certify  that 

[COMPANY_001] Confidential Page 61
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigator will receive copi[INVESTIGATOR_131540]. 
8.3 Database management and quality  control 
[COMPANY_001] personnel (or designated C ontract Research Organization (CRO) will review the data 
entered by [CONTACT_5375] . Electronic data queries stating 
the nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigationa l site via the EDC system. Designated 
investigator site staff is required to respond promptly  to queries and to make any necessary 
changes to the data. 
Concomitant medications entered into the database will be coded using the World Health 
Organization ( WHO)Drug Reference List, which employ s the Anatomical Therapeutic 
Chemical classification system. Concomitant procedures, non-drug therapi[INVESTIGATOR_18541] (MedDRA) 
terminology .
Labora tory samples will be processed centrall y and the results will be sent electronicall y to 
[COMPANY_001] (or a designated CRO).
ECGs will be analyzed centrall y and results will be sent electronicall y to [COMPANY_001] (or a 
designated CRO). Any clinically  significant findings will be reported as (cardiovascular) 
medical history  or AE depending upon timing of ECG assessment compared to screening.
 
 
Randomization codes and data about all study  drug(s) dispensed to the subject and all dosage 
changes will be tracked using an Interactive Response Technology  (IRT). The system will be 
supplied by a vendor, who will also manage the database. The data will be sent electronicall y 
to [COMPANY_001] (or a designated CRO).
Each occurrence of a code break via IRT will be reported to the clinical team and monitor . 
The code break functionality  will remain available until study  shut down or upon request of 
[COMPANY_001]. 
The occurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accur ate, it will be 
locked and the treatment codes will be unblinded and made available for data analysis. Any 
changes to the database after that time can only be made after written agreement by [CONTACT_18660].
8.4 Data Monitoring Committee 
Not r equired.

[COMPANY_001] Confidential Page 62
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
8.[ADDRESS_148533] data at the time the trial ends. Any data analysis 
carried out independently  by [CONTACT_105278].
9.1 Analysis sets 
The following anal ysis sets will be used in this trial:
Randomized set: The randomized set will be defined as all subjects who were randomized. 
Unless otherwise specified, mis-
randomized subjects (mis- randomized in IRT) will be 
excluded from the randomized set. 
Full analysis set (FAS): The FAS will be comprised of all subjects from the randomized set 
to whom study  treatment has been assigned. Following the intent -to-treat principle, subjects 
will be anal yzed according to the treatment assigned to at randomization. 
Safety set (SAF) : The safet y set includes all subjects who took at least one dose of study
treatment during the treatment period. Subjects will be analyzed according to treatment 
received.
9.2 Patient demographics and other baseline characteristics 
Demographics and baseline characteristics
Summary  statistics will be presented for continuous demograp hic and baseline characteristic 
variables for each treatment group and for all subjects in the randomized set. The numbe r and 
percentage of subjects in each category  will be presented forcategorical variables for each 
treatment group and for all subjects.
Medical history
Any condition entered as medical history  or current medical conditions at baseline will be 
coded using the MedDRA dictionary . Medical history  will be summarized by [CONTACT_131571] . Summaries for psoriasis specific medical 
history  will be provided as well.
9.3 Treatments 
Study treatments
The anal ysis of study  treatme nt data will be based on the safet y set.
The number of active and placebo injections will be summarized by  [CONTACT_131572].

[COMPANY_001] Confidential Page 63
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
The duration of exposure to study  treatment will also be summarized by [CONTACT_1570]. In 
addition, the number of subjects with exposure of at least certain thresholds (e.g., any 
exposure, ≥1 week, ≥2 weeks, ≥3 weeks, ≥ 4 weeks, ≥8 weeks, etc.) will be display ed.
Prior and concomitant treatments
Prior and concomitant treatments will be summarized by [CONTACT_131573] y set.
Prior treatments are defined as treatments taken and stopped prior to first dose of study 
treatment. Any treatment given at least once between the day of first dose of randomized
study  treatment and the las t day  of study  visit will be a concomitant treatment, including those 
which were started pre -baseline and continued into the treatment period .
Treatments will be presented in alphabetical order, by [CONTACT_6977] 
(ATC) codes and main groups. Tables will also show the overall number and percentage of 
subjects receiving at least one treatment of a particular ATC code and at least one treatment in 
a particular anatomical main group.
Psoriasis specific prior treatments will be presented aswell including 
number of prior 
systemic and biologic psoriasis therapi[INVESTIGATOR_131541].
In addition, medical procedures and significant non-drug therapi[INVESTIGATOR_85674].
9.4 Analysis of the primary  variable(s)
This section will detail the statistical analy sis of the primary  endpoint . Details of the 
hypothesis testing strategy  including primary  and secondary  endpoints to handle multiplicity  
are provided in Secti on 9.5.1.
9.4.1 Primary  Variable(s)
The primary  efficacy  variable is PASI 90 response at Week 16. The analysis of primary  
variable will be based on the FAS .
9.4.2 Statistical model, hypothesis, and method of analy sis
The statistical hypothesis for PASI  90 response at Week 16being tested is that secukinumab 
300mgevery  2  weeks is not superior in the proportion of subjects with PASI  90 response at 
Week 16versus secukinumab 300 mgevery  4weeks .
 
The following h ypotheses will be tested
H1: p1–
p0≤0 versus H A1: p1– p0> 0,
In other words:

[COMPANY_001] Confidential Page 64
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
H1:secukinumab 300mgevery  [ADDRESS_148534] toPASI 90
response at Week 16.
The primary  analysis method will be the 
logistic regression model with treatment group and
baseline weight, baseline PASI score as explanatory  variables. Odds ratio will be computed 
for the comparison of secukinumab 300mgevery  2 weeks versus secukinumab 300mgevery 
4weeks utilizing the logistical regression model fitted. In case of non-convergence , Fisher ’s 
exact tes
t will be applied. Confidence intervals for risk difference will be provided.
The hy potheses H1will be tested at level 2.5% (one -sided) .
9.4.3 Handling of missing values/censoring/discontinuations
Response variables based on PASI  score and IGA mod 2011 score will be imputed with 
multiple imputation (MI) as primary  imputation method for the missing values. Multiple 
imputation (MI) is a simulation based approach where missing values are replaced by  [CONTACT_131574], creating multiple completed data sets. These completed data sets can then be 
analyzed using standard methods. Within this analy sis the PASI score or IGA mod [ADDRESS_148535] to response variables based on PASI  score and IGA mod 2011 
score will be imputed with non-response regardless of the reason for missing data (e.g., 
premature study  discontinuation, missed visit, administrative issues) , with the exception of the 
followings:
If a subject dropped out the study  prior to last scheduled visit and being responder 
consecutivel yat least for two pr eceding visits, the subject will be imputed as responder for 
the last scheduled visit.
If a subject who was responder at visit x -1 and visit x+[ADDRESS_148536] 
visit in the treatment period.
9.5 Analysis of secondary  variables
9.5.1 Efficacy  variables 
The secondary  variable in testing strategy  is the IGA mod 2011 
0 or 1 response at Week 16
(for superiorit y comparison of secukinumab 300mgevery  2  weeks versus secukinumab
300mgevery  4weeks ). The IGA mod 2011 0 or 1 response at Week 16will be analy zed 
analogously  to PASI 90 response at Week 16(i.e., logistic regression anal ysis).
The anal ysis of secondary  variable will be based on FAS.

[COMPANY_001] Confidential Page 65
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
H2: secukinuma b [ADDRESS_148537] toIGA mod 2011 0 or 1 response at Week 16.
Testing strategy
The famil y-wise type-I
-error will be set to α=2.5% (one-sided). The graphical approach of 
Bretz (Bretz et al 2009 ) for sequentiall y rejective testing procedures is used to illustrate the 
hierarchical testing strategy .
One-sided p-values will be derived. Each hypothesis is tested sequentially  at α=2.5% (one-
sided). The testing sequence will continue to H2at α(one-sided) onl y if H1has been rejected.
9.5.2 Safety  variables
All safet y evaluations will be performed on the Safety set.
Adverse events
Treatment -emergent adverse events will be summarized. Only  primary  paths within MedDRA 
will be considered for adverse event reporting. The definition for “treatment -emergent ”is as 
follows:
Events started after the first dose of study  medication or events present pr ior to the first 
dose of study  medication but increased in severit y based on preferred term
Started prior to the last dose plus 84 day s (inclusive)
AEs will be summarized by [CONTACT_1601], for each treatment group, the number and percentage 
of subjects having at least one AE, having an AE in each primary  system organ class and 
having each individual AE (preferred term). 
Summaries will also be presented for AEs by [CONTACT_131575]. If 
a particular AE ‘severity ’ is missing, this variable will be listed as missing and treated as 
missing in summaries. If a subject reported more than one adverse event with the same 
preferred term, the adverse event with the greatest severit y will be presented. If a subject 
reported more than one adverse event within the same primary  system organ class, the subject 
will be counted only once with the greatest severity  at the system organ class level, where 
applicable.

[COMPANY_001] Confidential Page 66
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Confidence intervals for relative frequencies will be derived as well according to the score 
method including continuity  correction b y Newcombe (Newcombe 1998 ).
Separate summaries will be provided for death, serious adverse event, other significant 
adverse events leading to discontinuation and adverse events leading to dose adjustment 
(including stud y treatment discontinuation).
Exposure adjusted incidence rates will be provided for selected adverse events. 
Laboratory  data
The summary  of laboratory  evaluation will be presented for three group s of laboratory  tests 
(hematology , serum chemistry  and urinal ysis). Descriptive summary  statistics for the change 
from baseline to each study  visit will be presented by [CONTACT_131576], laboratory  tests 
(i.e., lab parameters) and treatment group. Change from baseline will only be summarized for 
subjects with both baseline and post baseline.
For each lab parameter, the maximum change (maximum decrease and maximum increase) 
from baseline will be analyzed analogousl y.
In addition, shift tables will be pr ovided for all lab parameters to compare a subject ’s baseline 
laboratory  evaluation relative to the most extreme post-baseline laboratory  test value. For the 
shift tables, the normal laboratory  ranges will be used to evaluate whether a particular 
laborator y test value was normal, low, or high for each visit value relative to whether or not 
the baseline value was normal, low or high. These summaries will be presented by [CONTACT_131577].
Vital signs
Analy sis in vital sign measurement using descriptive summary  statistics for the change from 
baseline for each post-baseline visit will be performed by [CONTACT_37297]. 
Change from baseline will only be summarized for subjects with both baseline and post-
baseline values.
ECG
Summary  statistics will be presented for ECG variables by  [CONTACT_3232].

[COMPANY_001] Confidential Page 67
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324

[COMPANY_001] Confidential Page 68
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
9.7 Interim Analyses
A primary  endpoint analysis (PEA) may be conducted when all subjects have completed the 
Week 16visit at which the primary  endpoint is assessed. Additional analyses may be 
performed to support health authority  interactions as necessary .

[COMPANY_001] Confidential Page 69
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
9.[ADDRESS_148538] a clinical relevant treatment difference (i.e. 15%) 
between secukinumab 300mgevery  two weeks and secukinumab 300mgevery  four weeks. 
Based on this, the total sample size is approximately 330subjects , with body  weight ≥ 90 kg 
at randomization. i.e., 165 subjects will be randomized to each dose regimen (300 g every  2 
weeks and 30 0mgevery  
4weeks ) using a balanced randomization.
Secukinumab 300mgevery  two weeks will be tested versus secukinumab 300mgevery  four 
weeks with respect to the primary  endpoint PASI 90 response at Week 16, and sequentiall y 
the secondary  endpoint IGA mod 2011 
0 or 1 at Week 16. The family -wise type -I-error will 
be 2.5% (one -sided)
 
 
 
 
 
 
10 Ethical considerations 
10.1 Regulatory  and ethical compliance 
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the International Conference on Harmonisation (ICH) Harmonized Tripartite 
Guidelines for Good Clinical Practice, with applicable local regulations (including European 
Directive 2001/20/EC, US CFR 21, and Japanese Ministry  of Health, Labor, and Welfare), 
and with the ethical principles laid down in the Declaration of Helsinki.
10.2 Informed consent procedur es 
Eligible subjects may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if applicable after 
such consent has been provided by a  legally  acceptable representati ve(s) of the subject . In 
cases where the subject ’s representative gives consent, the subject must be informed about the 
study  to the extent possible given his/her understanding. If the subject is capable of doing so, 
he/she must indicate assent by [CONTACT_131578] a separate assent form. Informed consent must be obtained before conducting 
any study-specific procedures (e.g. all of the procedures described in the protocol). The 
process of obtaining informed consent must be documented in the subject source documents. 
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory  requirements and is 

[COMPANY_001] Confidential Page 70
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
considered appropriat e for this study . Any  changes to the proposed consent form suggested by  
[CONTACT_90219]/IEC and a copy 
of the approved version must be provided to the [COMPANY_001] monitor after IRB/IEC approval.
Wome n of child bearing potential must be informed that taking the study  treatment may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requi rement for the 
duration of the study . If there is any question that the subject will not reliably  comply , they 
must not be entered in the study .
10.3 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_50074]/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g., advertisements) and any  other wr itten information to be provided to subjects . 
Prior to study  start, the investigator is required to sign a protocol signature [CONTACT_16066]/her agreement to conduct the study  in accordance with these documents and all of the 
instructions and procedur es found in this protocol and to give access to all relevant data and 
records to Novarti s monitors, auditors, [COMPANY_001] Quality  Assurance representatives, designated 
agents of [COMPANY_001], IRBs/I ECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform [COMPANY_001] 
immediately  that this request has been made.
10.4 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report 
the results of this trial will be either submitted for publication and/or posted in a publicly  
accessible database of clinical trial res ults.
10.[ADDRESS_148539] Quality  Management (QM) system that includes all activities 
involved in quality  assurance and qualit y control, including the assignment of roles and 
responsibilities, the reporting ofresults, and the documentation of actions and escalation of 
issues identified during the review of qualit y metrics, incidents, audits and inspections.
Audits of investigator sites, vendors, and [COMPANY_001] sy stems are performed by  [CONTACT_105295], a group independent from those involved in 
conducting, monitoring or performing quality  control of the clinical trial. The clinical audit 
process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compl iance with global and local regulatory  requirements, 
protocols and internal Standard Operating Procedures (SOPs) , and are performed according to 
written [COMPANY_001] processes.

[COMPANY_001] Confidential Page 71
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
[ADDRESS_148540] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and health authorities, where required, it cannot be 
implemented. 
11.[ADDRESS_148541] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
imple mentation. Only  amendments that are intended to eliminate an apparent immediate 
hazard to subjects may be implemented immediately  provided the health authorities are 
subsequently  notified by [CONTACT_6670]/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section [ADDRESS_148542] .
Bretz F, Maurer W, Brannath W, et al (2009) A graphical appro ach to sequentially  rejective 
multiple test procedures. Statist. Med; 28:586 -604.
Chobanian AV, Bakris GL, Black HR, et al (2003) Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 
Hypertension; 42:1206- 1252.
Committee for medicinal products for human use (CHMP), European Medicines Agency  for 
the Evaluation of Medicines for Human Use (2004) Guideline on clinical investigation of 
medicinal products indicated for the treatment of psoriasi s. CHMP/EWP/2454/02 corr 
document. London, [LOCATION_006].
Dohert y SD, Van Voorhees A, Lebwohl MG, et al (2008) National Psoriasis Foundation 
consensus statement on screening for latent tuberculosis infection in patients with psoriasis 
treated with s ystemic and biolog ic agents. J Am Acad Dermatol; 59(2):209 -217. 
 
 

[COMPANY_001] Confidential Page 72
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Fredriksson T, Pettersson U (1978) Severe Psoriasis – Oral Therap y with a New Retinoid.  
Dermatologica; 157:238 -244.
Gottlieb AB, Griffiths CEM, Ho VC, et al (2005) Oral pi[INVESTIGATOR_131542]- type psoriasis: a double –blind, multicenter, randomized, 
dose-finding trial. British Journal of Dermatology ; 152:1219 -1227.
Kimball AB, Wu EQ, Guerin A, et al (2012) Risk of developi[INVESTIGATOR_131543]. J Am Acad Dermatol; 67 (4):651 -7.
Langley  RG, Elewski BE, L ebwohl M, et al (2014) Secukinumab in Plaque Psoriasis -Results 
of Two Phase 3 Trials. N ENGL J MED; 371 (4): 326-338.
Mancia G, De Backer G, Dominiczak A, et al (2007) 2007 Guidelines for the Management of 
Arterial Hy pertension. Journal of Hy pertension; 25:1105-1187.
Manuel O, Kumar D (2008) QuantiFERON -TB Gold assay  for the diagnosis of latent 
tuberculosis infection. Expert rev. Mol. Diagn; 8(3):247-255.
Newcombe RG (1998) Two
-sided confidence intervals for the single proportion: comparison 
of seven methods. Statistics in Medicine; 17:857-872.
Papp KA (2006) The long -term efficacy  and safety  of new biological therapi[INVESTIGATOR_109006]. 
Arch Dermatol Res; 298:7-15.
Papp KA, Langley RG, Lebwohl M, et al (2008) Efficacy  and Safety  of ustekinumab, a 
human interleukin -12/23 monoclonal antibody , in patients with psoriasis: 52 -week results 
from a randomised, double- blind, placebo -controlled trial (PHOENIX 2) . Lancet; 371:1675-
84.
Thaci D, Blauvelt A, Reich K, et al (2015) Secukinumab is superior to ustekinumab in 
clearing skin of subjects with moderate to severe plaque psoriasis: CL EAR, a randomized 
controlled trial. J Am ACAD Dermatol; 73 (3):400 -409.
van L ümig PPM, Lecluse LLA, Driessen RJB, et al (2010) Switching from etanercept to 
adalimumab is effective and safe: results in 30 patients with psoriasis with primary  failure, 
secondary  failure or intolerance to etanercept. British Journal of Dermatology ; 163: 838-846.
Weisman S, Pollack CR, Gottschalk RW (2003) Psoriasis disease severity  measures: 
comparing efficacy  of treatments for severe psoriasis. Journal of Dermatological Treatment; 
14:158 -
165. 

[COMPANY_001] Confidential Page 73
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
13 Appendices
13.1 Appendix 1: Clinically  notable laboratory  values and vital signs
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory  tests. Notable values for blood pressure and pulse are presented in Section 6.5.2.
No specific action is pre-defined within this protocol to respond to specific abnormal 
laboratory  values, as it will be decided by [CONTACT_131579], taking into ac
count the overall status of 
the subject .
Liver Function and Related Variables
Alanine transaminase (ALT) (SGPT): > 3 x Upper L imit of Normal (ULN)
Aspartate transaminase (AST) (SGOT): > 3 x UL N
Total bilirubin: > 2 x UL N
Alkaline phosphatase: > 2.[ADDRESS_148543]
Hematology  Variables
Hemoglobin: ≥ 20 g/dL decrease from baseline
Platelet count: < Lower L imit of Normal (LLN)
White blood cell count: < 0.[ADDRESS_148544]
Neutrophils: < 0.[ADDRESS_148545]
Eosinophils: > 1.1 x UL N
Lym phocy tes: > 1.1 x UL N

[COMPANY_001] Confidential Page 74
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
13.2 Append ix 2: Liver event and Laboratory  trigger Definitions and 
Follow -up Requirements
Table 13-1 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY TRIGGERS [ADDRESS_148546] < ALT / AST [ADDRESS_148547]
1.[ADDRESS_148548] < TBL [ADDRESS_148549]
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5 
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and 
TBL > 2 × ULN [mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, 
abdominal pain, nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms
TBL: total bilirubin; ULN: upper limit of normal ; INR: international normalized ratio
Table 13-2 Follo w-upRequirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law 
caseaDiscontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete appropriate CRF to record the 
AE and any contributory factorsALT, AST, TBL, Alb, PT/INR, ALP and 
GGT until resolutionc(frequency at 
investigator discretion)
ALT or AST
> 8 × ULN Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete appropriate CRF to record the 
AE and any contributory factorsALT, AST, TBL, Alb, PT/INR, ALP and 
GGT until resolutionc(frequency at 
investigator discretion)
> 3 × ULN and INR > 
1.5Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete appropriate CRF to record the 
AE and any contributory factorsALT, AST, TBL, Alb, PT/INR, ALP and 
GGT until resolutionc(frequ ency at 
investigator discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue follow -up 
monitoring
If elevation persists for more than [ADDRESS_148550], TBL, Alb, PT/INR, ALP and 
GGT until resolutionc(frequency at 
investigator discretion)

[COMPANY_001] Confidential Page 75
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
Criteria Actions required Follow -up monitoring
Establish causality
Complete appropriate CRF to record the 
AE and any contributory factors
> 3 × ULN 
accompanied by 
[CONTACT_18688]Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete appropriate CRF to record the 
AE and any contributory factorsALT, AST, TBL, Alb, PT/INR, ALP and 
GGT until resolutionc(frequency at 
investigator discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4weeks
ALP (isolated)
> 2 × ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish causality
Complete appropriate CRF to record the 
AE and any contributory factorsInvestigator discretion
Monitor LFT within 1 to 4weeks or at 
next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the study 
drug immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete appropriate CRF to record the 
AE and any contributory factorsALT, AST, TBL, Alb, PT/INR, ALP and 
GGT until resolutionc(frequency at 
investigator discretion)
Test for hemolysis (e.g., reticulocytes, 
haptoglobin, unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate c lose 
observation of the patient Investigator discretion
Monitor LFT within 1 to 4weeks or at 
next visit
Jaundice Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18554]
Establish causality
Complete appropriate CRF to record the 
AE and any contributory factorsALT, AST, TBL, Alb, PT/INR, ALP and 
GGT until resolutionc(frequency at 
investigator discretion)
Any AE potentially 
indicative of a liver 
toxicity*Consider study treatment interruption or 
discontinuation 
Hospi[INVESTIGATOR_6549]
Establish causality
Complete appropriate CRF to record the 
AE and any contributory factorsInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fa tigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at 
three subsequent monitoring visits at least 2 weeks apart, (3) remain a t elevated level after a maximum of 
6months , (4) liver transplantation, and (5) death.

[COMPANY_001] Confidential Page 76
Clinical Trial Protocol (Version 00) Protocol No. C AIN457A2324
